Medicaments, compositions and methods for treating and / or preventing vitamin K2 deficiency
By promoting the production of vitamin K2 in the intestines through prebiotics, the problem of vitamin K2 deficiency is solved, thus achieving the effect of improving health functions.
Patent Information
- Application Number
- CN202410655273.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-25
- Filing Date
- 2024-05-24
- Publication Date
- 2024-11-26
AI Technical Summary
In the existing technology, vitamin K2 deficiency leads to a variety of health problems, and there are no effective nutritional interventions for individuals who develop secondary vitamin K2 deficiency after using vitamin K antagonists or long-term use of antibiotics or glucocorticoids.
By using prebiotics such as bovine milk oligosaccharides (BMO), human milk oligosaccharides (HMO), and fiber oligosaccharides (COS), vitamin K2 production in the gut of subjects was promoted, including de novo production of methylnaphthoquinone-7 and bioconversion of chloroquinone to methylnaphthoquinone-4.
It effectively treats and prevents vitamin K2 deficiency, increases vitamin K2 levels in the gut of subjects, and improves biological functions such as bone mineralization, endothelial function, and joint health.
Smart Images

Figure CN119015429A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to agents, compositions and methods for treating and / or preventing vitamin K2 deficiency in a subject. The present invention also relates to agents, compositions and methods for promoting the production of vitamin K2 in the intestinal tract of a subject. Background Art
[0002] Vitamin K2 activates vitamin K-dependent proteins that support many biological functions, such as bone mineralization, inhibition of vascular stiffness, improved endothelial function, maintenance of strong teeth, brain development, joint health, and optimal body weight ( -Kozakowska, A. and Maresz, K., 2022. Children, 9(1), p. 78).
[0003] However, vitamin K2 intake by parents and their offspring has declined significantly over the past few decades, leading to serious health problems. In addition, people who consume adequate amounts but have malabsorption disorders or liver disease may develop secondary vitamin K2 deficiency when taking vitamin K antagonist medications, or after long-term use of antibiotics or glucocorticoids.
[0004] Therefore, new nutritional interventions are needed to treat and / or prevent vitamin K2 deficiency. Summary of the invention
[0005] The present inventors surprisingly found that vitamin K2 production in the gastrointestinal tract (eg, via conversion of vitamin K1) is promoted by prebiotic agents, such as bovine milk oligosaccharides (BMOs), human milk oligosaccharides (HMOs) and / or cellooligosaccharides (COS).
[0006] In one aspect, the present invention provides a prebiotic agent for use in treating and / or preventing vitamin K2 deficiency in a subject.
[0007] In another aspect, the present invention provides use of a prebiotic agent in the manufacture of a medicament for treating and / or preventing vitamin K2 deficiency in a subject.
[0008] In another aspect, the present invention provides a method for treating and / or preventing vitamin K2 deficiency in a subject in need thereof, the method comprising administering to the subject an effective amount of a prebiotic agent.
[0009] The prebiotic agent can treat or prevent vitamin K2 deficiency by promoting vitamin K2 production in the subject's intestine. For example, the prebiotic agent can treat or prevent vitamin K2 deficiency by promoting the de novo production of menaquinone-7 and / or the bioconversion of phylloquinone to menaquinone-4 in the subject's intestine.
[0010] In another aspect, the present invention provides the use of a prebiotic agent to promote the production of vitamin K2 in the intestine of a subject.
[0011] In another aspect, the present invention provides a method for promoting vitamin K2 production in the intestine of a subject, the method comprising administering to the subject an effective amount of a prebiotic agent.
[0012] The prebiotic agent can be any suitable prebiotic agent that promotes the production of vitamin K2 in the intestinal tract of the subject. Suitably, the prebiotic agent is selected from one or more of the following: bovine milk oligosaccharides (BMO), human milk oligosaccharides (HMO), cellobiose, cello-oligosaccharides (COS), inulin, lactose, fructooligosaccharides (FOS), galacto-oligosaccharides (GOS) and beta-glucan. In some embodiments, the prebiotic agent is selected from one or more of the following: bovine milk oligosaccharides (BMO), human milk oligosaccharides (HMO) mixture and cello-oligosaccharides (COS).
[0013] In some embodiments, the prebiotic agent comprises BMO in an amount of about 80 wt % to about 100 wt % relative to the total weight of the prebiotic agent.
[0014] In some embodiments, the prebiotic agent comprises or consists of one or more HMOs. In some embodiments, the prebiotic agent comprises or consists of at least one sialylated oligosaccharide, at least one fucosylated oligosaccharide and / or at least one N-acetylated oligosaccharide. Suitably, at least one sialylated oligosaccharide is selected from the group consisting of 3'-sialyllactose (3'-SL), 6'-sialyllactose (6'-SL), sialyllactose-N-tetrasaccharide b (LSTb), sialyllactose-N-tetrasaccharide c (LSTc), disialyllactose-N-tetrasaccharide, and combinations thereof. In some embodiments, at least one sialylated oligosaccharide is selected from 3'-sialyllactose (3'-SL), 6'-sialyllactose (6'-SL), and combinations thereof. Suitably, at least one fucosylated oligosaccharide is selected from the group consisting of 2'-fucosyllactose (2'FL), 3-fucosyllactose (3FL), difucosyllactose (diFL), lactose-N-fucopentose-I (LNFP-I), lactose-N-fucopentose-II (LNFP-II), lactose-N-fucopentose-III (LNFP-III), lactose-N-fucopentose-V (LNFP-V), lactose-neofucopentose V (LNnFP-V), lactose-N-difucosylhexose-I (LNDFH-1), lactose-N-neodifucosylhexose (LNnDFH), monofucosyllactose-N-hexose-III (MFNLH-III), difucosyllactose-N-hexose-a (DFLNHa) and combinations thereof. In some embodiments, at least one fucosylated oligosaccharide is 2'-fucosyllactose (2'FL) and / or difucosyllactose (diFL). Suitably, at least one N-acetylated oligosaccharide is selected from the group consisting of: N-acetyl-glucosamine, N-acetyl-galactosamine, lactose-N-tetraose (LNT), lactose-N-neotetraose (LNnT) and combinations thereof. In some embodiments, at least one N-acetylated oligosaccharide is selected from lactose-N-tetraose (LNT), lactose-N-neotetraose (LNnT) and combinations thereof.
[0015] In some embodiments, the prebiotic agent comprises or consists of cellooligosaccharides (COS).
[0016] The prebiotic agent can be administered to the subject in any suitable amount. Suitably, the prebiotic agent is administered to the subject in a total amount of about 0.5 g / day to about 10 g / day. Suitably, BMO is administered to the subject in a total amount of about 0.5 g / day to about 10 g / day. Suitably, HMO is administered to the subject in a total amount of about 0.5 g / day to about 10 g / day. Suitably, cellooligosaccharides (COS) are administered to the subject in a total amount of about 0.5 g / day to about 10 g / day.
[0017] Prebiotics can be administered in combination with vitamin K1. Vitamin K2 can be formed by metabolic conversion of vitamin K1 during its absorption in the intestinal mucosa and other organs. Prebiotics and vitamin K1 can be administered separately, simultaneously or sequentially. In a preferred embodiment, prebiotics and vitamin K1 are administered simultaneously. Suitably, vitamin K1 is administered to a subject in an amount of about 5 μg / day to about 200 μg / day.
[0018] Prebiotics can be administered in combination with probiotics. The inventors have surprisingly found that vitamin K2 production in the gastrointestinal tract (e.g., via conversion of vitamin K1) can be further promoted by administering probiotics. Prebiotics and probiotics can be administered separately, simultaneously, or sequentially. In a preferred embodiment, prebiotics and probiotics are administered simultaneously. Probiotics can comprise any suitable probiotics. Suitably, probiotics include Lactobacillus rhamnosus, Bifidobacterium infantis, and / or Bifidobacterium lactis. Suitably, the probiotic is administered at about 10 6 cfu / day to about 10 12 A total amount of 10 cfu / day was administered to the subjects.
[0019] The prebiotic agent (or combination thereof) can be provided in any suitable form (e.g., in the form of a composition). The prebiotic agent (or combination thereof) can be provided in the form of a nutritional composition. The prebiotic agent (or combination thereof) can be provided in the form of a medical food product for clinical nutrition.
[0020] Suitably, the composition comprises a total amount of prebiotic agent of about 0.5 g / 100 g to about 10 g / 100 g on a dry weight basis. Suitably, the composition comprises vitamin K1 in an amount of about 5 μg / 100 g to about 200 μg / 100 g on a dry weight basis. Suitably, the composition comprises vitamin K1 in an amount of about 10 6 cfu / 100g to about 10 12 cfu / 100g of probiotics.
[0021] The subject can be any suitable subject. Suitably, the subject is a human or an animal. In a preferred embodiment, the subject is a human. In some embodiments, the subject is a teenager, a teenager, a child, a toddler or an infant. In some embodiments, the subject is a child, a toddler or an infant. In other embodiments, the subject is an adult. The subject may suffer from or may be at risk of vitamin K2 deficiency. In some embodiments, the subject suffers from dyslipidemia, diabetes, major thalassemia (TM), cystic fibrosis (CF), inflammatory bowel disease (IBD) or chronic liver disease or has the risk of suffering from the dyslipidemia, diabetes, major thalassemia (TM), cystic fibrosis (CF), inflammatory bowel disease (IBD) or chronic liver disease. In some embodiments, the subject suffers from bone growth and / or bone strength reduction or has the risk of suffering from the bone growth and / or bone strength reduction. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1 - Effects of human milk oligosaccharides (HMO) on vitamin K2 production in a gut model The following groups were evaluated: blank; single HMO (1.3 g / L 2FL); HMO mixture (2.5 g / L 2FL, DiFL, LNnT, LNT, and 6SL); Bifidobacterium infantis (10 7 cfu / ml); single HMO + Bifidobacterium infantis; HMO mixture + Bifidobacterium infantis.
[0023] Figure 2 - Effects of oligosaccharides and probiotics on vitamin K2 production in a gut model
[0024] (A) The following groups were evaluated (in the absence of milk matrix): blank; and HMO + BMO (7.2 g / L total). (B) The following groups were evaluated: blank; MM (milk matrix containing a mixture of 6 HMOs); MM + B. infantis (10 11 cfu / g).
[0025] Figure 3 - Effects of human milk oligosaccharides (HMO) on vitamin K2 production in a gut model
[0026] (A) The following groups were evaluated (in milk matrix, in the absence of Lactobacillus rhamnosus LPR): blank; COS (2700 mg / L); COS (2025 mg / L) + β-glucan (675 mg / L); and COS (2025 mg / L) + β-glucan (675 mg / L) + Bifidobacterium lactis (4.5 × 10 6 cfu / ml). (B) The following groups were evaluated (in milk matrix, in the presence of 4.5×10 7cfu / ml Lactobacillus rhamnosus LPR): blank; COS (2700 mg / L); COS (2025 mg / L) + β-glucan (675 mg / L); and COS (2025 mg / L) + β-glucan (675 mg / L) + Bifidobacterium lactis (4.5 × 10 6 cfu / ml). (C) The following groups were evaluated (in milk matrix): without LPR (no L. rhamnosus LPR added); and with LPR (4.5×10 7 cfu / ml Lactobacillus pruinosa LPR).
[0027] Figure 4 - Preclinical experimental design
[0028] Growth-retarded group (with vitamin K1): The number of pups per BALB / c dam was increased by 50% from D8 to D18 to induce food restriction. In both groups (normal and growth-retarded), weaning occurred at D18. Male and female mice were then fed ad libitum and supplemented daily by pipette for 30 days.
[0029] Figure 5 A and Figure 5 B-Effects of vitamin K2AD on trabecular BV / TV and Effects of cortical BMD.
[0030] As previously described, micro-computed tomography (μCT UCT35, Scanco Medical AG, Basserdorf, Switzerland) was used to evaluate the trabecular and cortical microarchitecture of the distal femur metaphysis and mid-shaft diaphysis, respectively. In brief, trabecular and cortical bone areas were evaluated using isotropic 6 μm voxels. For the trabecular area of the femur, 30 bone sections below the distal growth plate were not considered to eliminate primary cancellous bone. 80 secondary cancellous bone sections just below were analyzed. The femoral cortical structure was evaluated using 60 consecutive CT sections located in the mid-shaft of the femur. Morphometric variables were calculated from the binarized images using a direct three-dimensional technique that does not rely on prior assumptions about the underlying structure. For the trabecular bone area, the BV / TV score (%) was evaluated. For the cortical bone at the mid-shaft of the femur, the cortical bone mineral density (Ct.BMD) was evaluated.
[0031] Figure 6 A and Figure 6 B-Evaluation of the effect of vitamin K2AD on femoral strength by 3-point bending test
[0032] As previously described, a 3-point bending test was performed to test the biomechanical properties of the femur (CH Turner, DB Burr, Basic biomechanical measurements of bone: a tutorial, Bone, 1993, 14 (4): 595-608). The load was applied in compression mode at a nominal deformation rate of 0.08 mm / s until fracture. The load-displacement curve was recorded to determine the fracture force (Fmax (N) / AP (mm)) standardized by the anterior-posterior diameter of the femur and the fracture energy (Wmax (N) / AP (mm)) standardized by the anterior-posterior diameter of the femur. DETAILED DESCRIPTION
[0033] Various preferred features and embodiments of the present invention will now be described by way of non-limiting examples. The skilled person will appreciate that they can combine all features of the present invention disclosed herein without departing from the scope of the invention disclosed.
[0034] Any reference to prior art documents in this specification cannot be regarded as an admission that such prior art is well-known technology or forms part of the common general knowledge in the field.All publications mentioned in the specification are incorporated herein by reference.
[0035] As used in this specification, the words "include / comprise" and similar words should not be understood to have an exclusive or exhaustive meaning. In other words, they are intended to mean "including, but not limited to". The term "include / comprise" and similar words also include the term "consisting of..."
[0036] Unless otherwise indicated, the practice of the present invention will adopt conventional techniques within the capabilities of those of ordinary skill in the art. Such techniques are described in the literature. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art.
[0037] Numerical ranges include the values that define the range, and unless otherwise stated, all percentages disclosed herein are based on w / w. As used herein, the term "about" means approximately, in the vicinity, roughly, or around. When the term "about" is used in conjunction with a numerical value or range, it modifies the value or range by extending the boundaries above and below the numerical value shown. Generally speaking, the terms "about" and "approximately" are used herein to modify the numerical values above and below the stated value by 10%.
[0038] Prebiotics
[0039] The present invention provides prebiotic agents for use in treating and / or preventing vitamin K2 deficiency in a subject.
[0040] As used herein, the term "prebiotic" may refer to a non-digestible component that benefits a subject by selectively stimulating the favorable growth and / or activity of one or more microbial groups. A prebiotic agent may be any suitable prebiotic agent that promotes the production of vitamin K2. Exemplary prebiotics include bovine milk oligosaccharides (BMOs), human milk oligosaccharides (HMOs), cellobiose, cellooligosaccharides (COS), inulin, lactose, fructooligosaccharides (FOS), galacto-oligosaccharides (GOS), and β-glucans.
[0041] In some embodiments, the prebiotic agent is selected from one or more of the following: bovine milk oligosaccharides (BMO), human milk oligosaccharides (HMO), cellobiose, cellooligosaccharides (COS), inulin, lactose, fructooligosaccharides (FOS), galacto-oligosaccharides (GOS), and β-glucan.
[0042] In some embodiments, the prebiotic agent is selected from one or more of the following: bovine milk oligosaccharides (BMO), human milk oligosaccharides (HMO) mixtures, and cello-oligosaccharides (COS). In some embodiments, the prebiotic agent comprises BMO and HMO. In some embodiments, the prebiotic agent comprises HMO. In some embodiments, the prebiotic agent comprises cello-oligosaccharides (COS).
[0043] Milk oligosaccharides
[0044] The prebiotic agent for use in the present invention may comprise or consist of bovine milk oligosaccharides (BMO).
[0045] Oligosaccharides in bovine milk are assembled in the mammary gland by combining the monosaccharides glucose (Glc), galactose (Gal), N-acetylglucosamine (GlcNAc), N-acetylgalactosamine, fucose, and sialic acid N-acetylneuraminic acid and N-glycolylneuraminic acid. The collection of BMOs found in milk and colostrum has been extensively characterized, with 30 to 50 structures typically identified in comprehensive studies (see, e.g., Robinson, RC, 2019. Frontiers in nutrition, 6, p. 50).
[0046] Although bovine milk generally contains fewer oligosaccharide structures than human milk, the two share at least ten common structures, including 3'-sialyllactose and 6'-sialyllactose, which make up a large percentage of the BMO pool (see, e.g., Robinson, RC, 2019. Frontiers in nutrition, 6, p. 50).
[0047] The prebiotic agent can comprise BMO in an amount of about 50 wt % or more, about 60 wt % or more, about 70 wt % or more, about 80 wt % or more, about 85 wt % or more, about 90 wt % or more, about 95 wt % or more, or about 100 wt % relative to the total weight of the prebiotic agent.
[0048] Human milk oligosaccharides (HMO)
[0049] The prebiotic agent for use in the present invention may comprise or consist of one or more human milk oligosaccharides (HMOs).
[0050] Many different kinds of HMOs are found in human milk and are generally based on combinations of glucose, galactose, sialic acid (N-acetylneuraminic acid), fucose and / or N-acetylglucosamine with many different linkages between them. Almost all HMOs have a lactose molecule at their reducing end, and the terminal position of the non-reducing end is occupied by sialic acid and / or fucose (if present). HMOs can be acidic (e.g., oligosaccharides containing charged sialic acid) or neutral (e.g., fucosylated oligosaccharides).
[0051] Suitably, one or more HMOs may comprise at least one fucosylated oligosaccharide, at least one sialylated oligosaccharide and / or at least one N-acetylated oligosaccharide. In some embodiments, one or more HMOs comprise or consist of at least one fucosylated oligosaccharide, at least one sialylated oligosaccharide and at least one N-acetylated oligosaccharide. In some embodiments, one or more HMOs comprise or consist of 2'-fucosyllactose (2'FL), difucosyllactose (diFL), 6'-sialyllactose (6'-SL), lactose-N-tetraose (LNT) and lactose-N-neotetraose (LNnT). In some embodiments, the one or more HMOs comprise or consist of 2'-fucosyllactose (2'FL), difucosyllactose (diFL), 6'-sialyllactose (6'-SL), 3'-sialyllactose (3'-SL), lacto-N-tetraose (LNT), and lacto-N-neotetraose (LNnT).
[0052] In some embodiments (e.g., when the prebiotic agent comprises BMO), the prebiotic agent comprises about 0.5 wt % to about 2 wt % of at least one fucosylated oligosaccharide relative to the total weight of the prebiotic agent. In some embodiments (e.g., when the prebiotic agent comprises BMO), the prebiotic agent comprises about 2 wt % to about 6 wt % of at least one sialylated oligosaccharide relative to the total weight of the prebiotic agent. In some embodiments (e.g., when the prebiotic agent comprises BMO), the prebiotic agent comprises about 1 wt % to about 4 wt % of at least one N-acetylated oligosaccharide relative to the total weight of the prebiotic agent.
[0053] In some embodiments (e.g., when the prebiotic agent comprises BMO), the prebiotic agent comprises from about 2 wt % to about 6 wt % of at least one fucosylated oligosaccharide, relative to the total weight of the prebiotic agent; and from about 1 wt % to about 4 wt % of at least one N-acetylated oligosaccharide, relative to the total weight of the prebiotic agent.
[0054] In some embodiments (e.g., when the prebiotic agent comprises BMO), the prebiotic agent comprises: about 2 wt % to about 6 wt % of at least one fucosylated oligosaccharide, relative to the total weight of the prebiotic agent; about 0.5 wt % to about 2 wt % of at least one sialylated oligosaccharide, relative to the total weight of the prebiotic agent; and about 1 wt % to about 4 wt % of at least one N-acetylated oligosaccharide, relative to the total weight of the prebiotic agent.
[0055] In other embodiments (e.g., when the prebiotic agent does not include BMO), the prebiotic agent comprises about 30% to about 80% by weight, about 40% to about 80% by weight, or about 50% to about 70% by weight of at least one fucosylated oligosaccharide relative to the total weight of the prebiotic agent. In some embodiments (e.g., when the prebiotic agent does not include BMO), the prebiotic agent comprises about 10% to about 35% by weight, about 10% to about 30% by weight, or about 10% to about 25% by weight of at least one sialylated oligosaccharide relative to the total weight of the prebiotic agent. In some embodiments (e.g., when the prebiotic agent does not include BMO), the prebiotic agent comprises about 10% to about 35% by weight, about 15% to about 30% by weight, or about 15% to about 20% by weight of at least one N-acetylated oligosaccharide relative to the total weight of the prebiotic agent.
[0056] In some embodiments (e.g., when the prebiotic agent does not comprise a BMO), the prebiotic agent comprises or consists of: about 30% to about 80%, about 40% to about 80%, or about 50% to about 70% by weight of at least one fucosylated oligosaccharide, relative to the total weight of the prebiotic agent; and about 10% to about 35%, about 15% to about 30%, or about 15% to about 20% by weight of at least one N-acetylated oligosaccharide, relative to the total weight of the prebiotic agent.
[0057] In some embodiments (e.g., when the prebiotic agent does not comprise a BMO), the prebiotic agent comprises or consists of: about 30% to about 80%, about 40% to about 80%, or about 50% to about 70% by weight of at least one fucosylated oligosaccharide, relative to the total weight of the prebiotic agent; about 10% to about 35%, about 10% to about 30%, or about 10% to about 25% by weight of at least one sialylated oligosaccharide, relative to the total weight of the prebiotic agent; and about 10% to about 35%, about 15% to about 30%, or about 15% to about 20% by weight of at least one N-acetylated oligosaccharide, relative to the total weight of the prebiotic agent.
[0058] HMO can be obtained by any suitable method. Suitable methods for synthesizing oligosaccharides are well known to those skilled in the art. For example, methods for preparing oligosaccharides by microbial fermentation, enzymatic methods, chemical synthesis or a combination of these techniques have been developed (see, for example, Zeuner et al., 2019.Molecules, Vol. 24, No. 11, p. 2033).
[0059] Fucosylated oligosaccharides
[0060] In one embodiment, the prebiotic agent comprises at least one fucosylated oligosaccharide.
[0061] Non-limiting examples of fucosylated oligosaccharides include: 2'-fucosyllactose (2'FL), 3-fucosyllactose (3FL), difucosyllactose (diFL), lactose-N-fucopentose (such as lactose-N-fucopentose I (LNFP-I), lactose-N-fucopentose II (LNFP-II), lactose-N-fucopentose III (LNFP-III), or lactose-N-fucopentose V (LNFP-V)), lactose-N-fucohexose, lactose-N-difucohexose I, lactose-neofucopentose V (LNFP-V), lactose-N-difucosylhexose-I (LNDFH-I), lactose-N-fucopentose II (LNFP-II), lactose-N-fucopentose III (LNFP-III), or lactose-N-fucopentose V (LNFP-V)). N-neodifucosyllactose-I (LNnDFH), fucosyllactose-N-hexose, fucosyllactose-N-neohexose (such as, fucosyllactose-N-neohexose I, fucosyllactose-N-neohexose II), monofucosyllactose-N-hexose III (MFNLH-III), difucosyllactose-N-hexose I, difucosyllactose-N-neohexose, difucosyllactose-N-neohexose I, difucosyllactose-N-neohexose II, difucosyllactose-N-hexose-a (DFLNHa), fucosyl-p-lactose-N-hexose, trifucosyl-p-lactose-N-hexose I and combinations thereof.
[0062] In a preferred embodiment, the at least one fucosylated oligosaccharide comprises 2'-fucosyllactose (2'FL), which is generally the most prevalent HMO naturally occurring in human breast milk.
[0063] In some embodiments, at least one fucosylated oligosaccharide is selected from the group consisting of: 2'-fucosyllactose (2'FL), difucosyllactose (diFL), and combinations thereof. In some embodiments, at least one fucosylated oligosaccharide comprises or consists of 2'-fucosyllactose (2'FL) and difucosyllactose (diFL).
[0064] Fucosylated oligosaccharides can be obtained by any suitable method. For example, 2'FL can be prepared by biotechnological means using specific fucosyltransferases and / or fucosidases, by using enzyme-based (recombinant or natural enzyme) fermentation techniques or microbial fermentation techniques. In the latter case, the microorganism can express its natural enzymes and substrates, or can be engineered to produce the corresponding substrates and enzymes. Alternatively, 2'FL can be produced by chemical synthesis from lactose and free fucose. diFL can be synthesized by enzymes, biotechnology and / or chemical methods.
[0065] Sialyl oligosaccharides
[0066] In some embodiments, the prebiotic agent comprises at least one sialylated oligosaccharide.
[0067] Non-limiting examples of sialylated oligosaccharides include 3'-sialyllactose (3'-SL), 6'-sialyllactose (6'-SL), sialyllactose-N-tetraose b (LSTb), sialyllactose-N-tetraose c (LSTc), disialyllactose-N-tetraose, and combinations thereof.
[0068] In some embodiments, at least one sialylated oligosaccharide is selected from the group consisting of: 3'-sialyllactose (3'-SL), 6'-sialyllactose (6'-SL), and combinations thereof. In some embodiments, at least one sialylated oligosaccharide comprises or consists of 6'-sialyllactose (6'-SL). In some embodiments, at least one sialylated oligosaccharide comprises or consists of 6'-sialyllactose (6'-SL) and 3'-sialyllactose (3'-SL).
[0069] Sialyl oligosaccharides can be obtained by any suitable method. For example, 3'-sialyllactose (3'-SL) and / or 6'-sialyllactose (6'-SL) can be isolated from natural sources (such as animal milk) using chromatography or filtration techniques. Alternatively, sialyllactose can also be prepared by biotechnology means, by fermentation techniques based on enzymes (recombinant enzymes or natural enzymes), by chemical synthesis or by microbial fermentation techniques, using specific sialyltransferases or sialidases, neuraminidase. In the latter case, the microorganism can express its natural enzymes and substrates, or can be engineered to produce corresponding substrates and enzymes. Single microbial cultures or mixed cultures can be used. Sialyl oligosaccharides can be formed initially with acceptor substrates of any degree of polymerization (DP), starting from DP=1. Alternatively, sialyllactose can be produced by chemical synthesis from lactose and free N'-acetylneuraminic acid (sialic acid). Sialyl lactose is also commercially available from, for example, Kyowa Hakko Kogyo, Japan or Gene Chem, Republic of Korea.
[0070] If the prebiotic agent comprises 3'-sialyllactose (3'-SL) and 6'-sialyllactose (6'-SL), it may be particularly advantageous that the 3'-sialyllactose (3'-SL) and 6'-sialyllactose (6'-SL) are included in the nutritional composition in a weight ratio of between about 10:1 and about 1:10, such as between about 10:1 and about 2:1, between about 8:1 and about 3:1, between about 6:1 and about 3:1, between about 5:1 and about 3:1, between about 5:1 and about 4:1, or between about 1:2 and about 1.5:1.
[0071] N-acetylated oligosaccharides
[0072] In some embodiments, the prebiotic agent comprises at least one N-acetylated oligosaccharide.
[0073] Suitably, at least one N-acetylated oligosaccharide is selected from the group consisting of: N-acetyl-glucosamine, N-acetyl-galactosamine and combinations thereof. Non-limiting examples of N-acetylated oligosaccharides include: LNT (lactose-N-tetraose), p-lactose-N-neohexose (p-LNnH), LNnT (lactose-N-neotetraose) and any combination thereof. Other examples are lactose-N-hexose, lactose-N-neohexose, p-lactose-N-hexose, p-lactose-N-neohexose, lactose-N-octose, lactose-N-neooctose, iso-lactose-N-octose, p-lactose-N-octose and lactose-N-decasaccharide.
[0074] In some embodiments, at least one N-acetylated oligosaccharide is selected from the group consisting of: lactose-N-tetraose (LNT), lactose-N-neotetraose (LNnT) and combinations thereof. In some embodiments, at least one N-acetylated oligosaccharide comprises or consists of lactose-N-tetraose (LNT) and lactose-N-neotetraose (LNnT).
[0075] N-acetylated oligosaccharides can be obtained by any suitable method. For example, LNnT can be chemically synthesized by enzymatic transfer of sugar units from donor moieties to acceptor moieties using glycosyltransferases. Alternatively, LNnT can be prepared by chemically converting free or oligosaccharide (e.g., lactulose)-bound ketone-hexose (e.g., fructose) into N-acetylhexosamine or oligosaccharides containing N-acetylhexosamine. LNT can be synthesized by enzymes, biotechnology and / or chemical methods.
[0076] Cellobiose and cellooligosaccharides (COS)
[0077] The prebiotic agent for use in the present invention may comprise or consist of cellobiose and / or cellooligosaccharides (COS).
[0078] Cellobiose is a disaccharide with the formula (C6H7(OH)4O)2O, which is derived from the condensation of a pair of β-glucose molecules forming a β(1→4) bond. Cellobiose can be obtained by enzymatic or acidic hydrolysis of cellulose and cellulose-rich materials. Suitably, cellobiose is in the form of free cellobiose or cellooligosaccharides.
[0079] In some embodiments, cellobiose is in the form of cellooligosaccharides (COS). Cello-oligosaccharides may refer to oligomers of β-glucose molecules (e.g., about 2 to about 6 β-glucose molecules) with β-1,4-bonds, and may mainly comprise cellobiose. The prebiotic agent used in the present invention may include or consist of cellooligosaccharides (COS). Studies have shown that COS has prebiotic potential (see, e.g., Zhong, C. et al., 2020. Journal of agricultural and foodchemistry, 68 (32), pp. 8557-8567).
[0080] Administration of prebiotics
[0081] Any suitable amount of a prebiotic can be administered to a subject in any suitable form and by any suitable route of administration (eg, in any form and by any route described herein).
[0082] For example, suitable doses of human oligosaccharides are described, for example, in the following: EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2015. EFSA Journal, 13 (11), p. 4299; EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), 2019. EFSA Journal, 17 (6), p. e05717; EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), 2020. EFSA Journal, 18 (5), p. e06097; EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), 2022. EFSA Journal, 20 (5), p. e07331; and EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), 2019. EFSA Journal, 17(12), p.e05907.
[0083] Suitably, the prebiotic agent is administered to the subject in an amount of at least about 0.5 g / day, at least about 1 g / day, or at least about 2 g / day. Suitably, the prebiotic agent is administered to the subject in an amount of about 10 g / day or less, about 8 g / day or less, or about 5 g / day or less. Suitably, the prebiotic agent is administered to the subject in an amount of about 0.5 g / day to about 10 g / day, about 1 g / day to about 8 g / day, or about 2 g / day to about 5 g / day.
[0084] Suitably, the BMO is administered to the subject in an amount of at least about 0.5 g / day, at least about 1 g / day, or at least about 2 g / day. Suitably, the BMO is administered to the subject in an amount of about 10 g / day or less, about 8 g / day or less, or about 5 g / day or less. Suitably, the BMO is administered to the subject in an amount of about 0.5 g / day to about 10 g / day, about 1 g / day to about 8 g / day, or about 2 g / day to about 5 g / day.
[0085] Suitably, the HMO is administered to the subject in an amount of at least about 0.5 g / day, at least about 1 g / day, or at least about 2 g / day. Suitably, the HMO is administered to the subject in an amount of about 10 g / day or less, about 8 g / day or less, or about 5 g / day or less. Suitably, the HMO is administered to the subject in an amount of about 0.5 g / day to about 10 g / day, about 1 g / day to about 8 g / day, or about 2 g / day to about 5 g / day.
[0086] Suitably, COS is administered to a subject in an amount of at least about 0.5 g / day, at least about 1 g / day, or at least about 2 g / day. Suitably, COS is administered to a subject in an amount of about 10 g / day or less, about 8 g / day or less, or about 5 g / day or less. Suitably, COS is administered to a subject in an amount of about 0.5 g / day to about 10 g / day, about 1 g / day to about 8 g / day, or about 2 g / day to about 5 g / day.
[0087] Combination therapy
[0088] The prebiotic agent may be administered in combination with one or more other agents, mixtures or compositions.
[0089] As used herein, "combination therapy" can refer to a therapy that includes the administration of two or more agents (eg, a prebiotic agent, one or more vitamins and / or a probiotic agent), mixtures, or compositions.
[0090] The combination may be administered by any suitable route and in any suitable form. Suitably, the combination is administered by oral and / or enteral administration. In a preferred embodiment, the combination is administered by oral administration. The combination may be administered individually, simultaneously or sequentially. In a preferred embodiment, the combination is administered simultaneously.
[0091] In one aspect, the invention provides a combination of a prebiotic agent, one or more vitamins (eg, vitamin K1), and one or more probiotics for use in treating and / or preventing vitamin K2 deficiency in a subject.
[0092] In another aspect, the present invention provides a use of a combination of a prebiotic agent, one or more vitamins (eg, vitamin K1), and one or more probiotics in the manufacture of a medicament for treating and / or preventing vitamin K2 deficiency in a subject.
[0093] In another aspect, the present invention provides a method for treating and / or preventing vitamin K2 deficiency in a subject in need thereof, the method comprising administering to the subject an effective amount of a combination of a prebiotic agent, one or more vitamins (e.g., vitamin K1), and one or more probiotics.
[0094] In another aspect, the present invention provides the use of a combination of a prebiotic agent, one or more vitamins (eg, vitamin K1) and one or more probiotics for promoting vitamin K2 production in the intestine of a subject.
[0095] In another aspect, the present invention provides a method for promoting vitamin K2 production in the intestine of a subject, the method comprising administering to the subject an effective amount of a combination of a prebiotic agent, one or more vitamins (eg, vitamin K1) and one or more probiotics.
[0096] Vitamins
[0097] Prebiotics can be administered in combination with one or more vitamins. Prebiotics and one or more vitamins can be administered separately, simultaneously or sequentially. In a preferred embodiment, prebiotics and one or more vitamins are administered simultaneously.
[0098] Vitamins are organic micronutrients required by the body for a range of normal functions and include vitamin K1, vitamin A, vitamin D, vitamin C, folic acid, vitamin B3, vitamin B6, vitamin B12 and vitamin E. Suitably, the one or more vitamins may comprise or consist of vitamin K1, vitamin K2, vitamin A and / or vitamin D. In a preferred embodiment, one or more vitamins may comprise or consist of vitamin K1.
[0099] In one aspect, the invention provides a combination of a prebiotic agent and one or more vitamins for use in treating and / or preventing vitamin K2 deficiency in a subject.
[0100] In another aspect, the present invention provides use of a combination of a prebiotic agent and one or more vitamins in the manufacture of a medicament for treating and / or preventing vitamin K2 deficiency in a subject.
[0101] In another aspect, the present invention provides a method for treating and / or preventing vitamin K2 deficiency in a subject in need thereof, the method comprising administering to the subject an effective amount of a combination of a prebiotic agent and one or more vitamins.
[0102] In another aspect, the present invention provides the use of a combination of a prebiotic agent and one or more vitamins for promoting vitamin K2 production in the intestine of a subject.
[0103] In another aspect, the present invention provides a method for promoting vitamin K2 production in the intestine of a subject, the method comprising administering to the subject an effective amount of a combination of a prebiotic agent and one or more vitamins.
[0104] Vitamin K1
[0105] In a preferred embodiment, the prebiotic agent may be administered in combination with vitamin K1. The prebiotic agent and vitamin K1 may be administered separately, simultaneously or sequentially. In a preferred embodiment, the prebiotic agent and vitamin K1 are administered simultaneously.
[0106] In one aspect, the invention provides a combination of a prebiotic agent and vitamin K1 for use in treating and / or preventing vitamin K2 deficiency in a subject.
[0107] In another aspect, the present invention provides use of a combination of a prebiotic agent and vitamin K1 in the manufacture of a medicament for treating and / or preventing vitamin K2 deficiency in a subject.
[0108] In another aspect, the present invention provides a method for treating and / or preventing vitamin K2 deficiency in a subject in need thereof, the method comprising administering to the subject an effective amount of a combination of a prebiotic agent and vitamin K1.
[0109] In another aspect, the present invention provides the use of a combination of a prebiotic agent and vitamin K1 for promoting the production of vitamin K2 in the intestine of a subject.
[0110] In another aspect, the present invention provides a method for promoting vitamin K2 production in the intestine of a subject, the method comprising administering to the subject an effective amount of a combination of a prebiotic agent and vitamin K1.
[0111] Vitamin K represents a family of fat-soluble compounds with the common chemical structure of 3-substituted 2-methyl-1,4-naphthoquinone. It occurs naturally in food as phylloquinone (vitamin K1) and menaquinone (vitamin K2). Vitamin K1 (phylloquinone) may have the following general formula:
[0112]
[0113] Vitamin K1 has a chlorophyll side chain and is generally the major dietary form of vitamin K and is found in dark green leafy vegetables (eg, spinach, lettuce, and other salad plants) and Brassicas.
[0114] Any suitable amount of vitamin K1 may be administered to a subject in any suitable form and by any suitable route of administration (e.g., in any form and by any route described herein). Suitable doses of vitamin K1 are described, for example, in the following: - Kozakowska, A. and Maresz, K., 2022. Children, 9(1), p. 78 and EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2017. EFSA Journal, 15(5), p. e04780.
[0115] Suitably, vitamin K1 is administered to the subject in an amount of at least about 0.2 μg / kg / day, at least about 0.5 μg / kg / day, or at least about 0.8 μg / kg / day. Suitably, vitamin K1 is administered to the subject in an amount of about 2 μg / kg / day or less, about 1.5 μg / kg / day or less, or about 1.2 μg / kg / day or less. Suitably, vitamin K1 is administered to the subject in an amount of about 0.2 μg / kg / day to about 2 μg / kg / day, about 0.5 μg / kg / day to about 1.5 μg / kg / day, or about 0.8 μg / kg / day to about 1.2 μg / kg / day. In some embodiments, vitamin K1 is administered to the subject in an amount of about 1 μg / kg / day.
[0116] Suitably, vitamin K1 is administered to a subject in an amount of at least about 5 μg / day, at least about 10 μg / day, at least about 15 μg / day, at least about 20 μg / day, at least about 25 μg / day, or at least about 30 μg / day. Suitably, vitamin K1 is administered to a subject in an amount of about 200 μg / day or less, about 100 μg / day or less, about 90 μg / day or less, about 80 μg / day or less, about 70 μg / day or less, or about 60 μg / day or less. Suitably, vitamin K1 is administered to a subject in an amount of about 5 μg / day to about 200 μg / day, about 10 μg / day to about 100 μg / day, about 15 μg / day to about 90 μg / day, about 20 μg / day to about 80 μg / day, about 25 μg / day to about 70 μg / day, or about 30 μg / day to about 60 μg / day.
[0117] Suitably, the prebiotic agent is administered to the subject in an amount of about 0.5 g / day to about 10 g / day, and vitamin K1 is administered to the subject in an amount of about 5 μg / day to about 200 μg / day.
[0118] Vitamin K2
[0119] Phylloquinone is a dietary vitamin K found in plants, while menaquinone is a vitamin K quinone consumed in the diet and produced by the gut microbiota (see, e.g., Walther, B. et al., 2013. Advances in nutrition, 4(4), pp. 463-473). In some embodiments, a prebiotic agent promotes the de novo production of menaquinone-7 in the gut of a subject (e.g., by the gut microbiota). In some embodiments, a prebiotic agent promotes the bioconversion of phylloquinone to menaquinone-4 in the gut of a subject (e.g., by the gut microbiota).
[0120] Vitamin K2 (menaquinone) may have the following general formula:
[0121]
[0122] Vitamin K2 consists of different forms, differing in the number of isoprene units (n), where n can range from 4 to 13. The various forms are indicated by the suffix (-n), for example, menaquinone-4 (abbreviated as MK-4) has four isoprene residues (n=4). MK-4 can be formed by metabolic transformation of phylloquinone during absorption in the intestinal mucosa and other organs. Other menaquinones can be produced in the gastrointestinal tract by the intestinal microbiota.
[0123] Prebiotics can be administered in combination with vitamin K2. Prebiotics and vitamin K2 can be administered separately, simultaneously or sequentially. In a preferred embodiment, prebiotics and vitamin K2 are administered simultaneously.
[0124] In one aspect, the invention provides a combination of a prebiotic agent and vitamin K2 for use in treating and / or preventing vitamin K2 deficiency in a subject.
[0125] In another aspect, the present invention provides use of a combination of a prebiotic agent and vitamin K2 in the manufacture of a medicament for treating and / or preventing vitamin K2 deficiency in a subject.
[0126] In another aspect, the present invention provides a method for treating and / or preventing vitamin K2 deficiency in a subject in need thereof, the method comprising administering to the subject an effective amount of a combination of a prebiotic agent and vitamin K2.
[0127] Any suitable amount of vitamin K2 may be administered to a subject in any suitable form and by any suitable route of administration (e.g., in any form and by any route described herein). Suitable doses of vitamin K2 are described, for example, in the following: - Kozakowska, A. and Maresz, K., 2022. Children, 9(1), p. 78 and European Food Safety Authority (EFSA), 2008. EFSA Journal, 6(11), p. 822.
[0128] Suitably, vitamin K2 is administered to the subject in an amount of at least about 0.5 μg / kg / day, at least about 1 μg / kg / day, or at least about 2 μg / kg / day. Suitably, vitamin K2 is administered to the subject in an amount of about 10 μg / kg / day or less, about 7.5 μg / kg / day or less, or about 5 μg / kg / day or less. Suitably, vitamin K2 is administered to the subject in an amount of about 0.5 μg / kg / day to about 10 μg / kg / day, about 1 μg / kg / day to about 7.5 μg / kg / day, or about 2 μg / kg / day to about 5 μg / kg / day.
[0129] Suitably, vitamin K2 is administered to a subject in an amount of at least about 5 μg / day, at least about 10 μg / day, at least about 15 μg / day, at least about 20 μg / day, at least about 25 μg / day, or at least about 30 μg / day. Suitably, vitamin K2 is administered to a subject in an amount of about 200 μg / day or less, about 100 μg / day or less, about 90 μg / day or less, about 80 μg / day or less, about 70 μg / day or less, or about 60 μg / day or less. Suitably, vitamin K2 is administered to a subject in an amount of about 5 μg / day to about 200 μg / day, about 10 μg / day to about 100 μg / day, about 15 μg / day to about 90 μg / day, about 20 μg / day to about 80 μg / day, about 25 μg / day to about 70 μg / day, or about 30 μg / day to about 60 μg / day.
[0130] Vitamin A
[0131] Vitamin A encompasses a family of molecules containing a 20-carbon structure with a methyl-substituted cyclohexenyl ring (β-ionone ring) and a tetraene side chain with a hydroxyl group (retinol), an aldehyde group (retinal), a carboxylic acid group (retinoic acid), or an ester group (retinyl ester) at carbon-15. The term vitamin A may also include provitamin A carotenoids, which are dietary precursors of retinol. Of the many carotenoids found in nature, some have provitamin A nutritional activity, including α-carotene, β-carotene, and β-cryptoxanthin.
[0132] The amount of vitamin A can be referred to as retinol equivalent (RE) or retinol activity equivalent (RAE). For the dietary provitamin A carotenoids β-carotene, α-carotene, and β-cryptoxanthin, RE is set to 6 μg, 12 μg, and 12 μg, respectively. When μg RAE is used, the vitamin A activity of the provitamin A carotenoid is half of the vitamin A activity assumed when μg RE is used. For the dietary provitamin A carotenoids β-carotene, α-carotene, and β-cryptoxanthin, RAE is set to 12 μg, 24 μg, and 24 μg, respectively. (See, e.g., Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington (DC): National Academies Press (US); 2001.4, Vitamin A).
[0133] Any suitable amount of vitamin A may be administered to a subject in any suitable form and by any suitable route of administration (e.g., in any form and by any route described herein). Suitable doses of vitamin A are described, for example, in Ross, AC and Moran, NE, 2020. Current Developments in Nutrition, 4 (10), p. nzaa096 and EFSA Panel on Dietetic Products, Nutrition, and Allergies (NDA), 2015. EFSA Journal, 13 (3), p. 4028.
[0134] Suitably, vitamin A is administered to a subject in an amount of at least about 100 μg RE / day, at least about 200 μg RE / day, or at least about 300 μg RE / day. Suitably, vitamin A is administered to a subject in an amount of about 1000 μg RE / day or less, about 800 μg RE / day or less, about 600 μg RE / day or less, or about 400 μg RE / day or less. Suitably, vitamin A is administered to a subject in an amount of about 100 μg RE / day to about 1000 μg RE / day, about 200 μg RE / day to about 800 μg RE / day, about 300 μg RE / day to about 600 μg RE / day, or about 300 μg RE / day to about 400 μg RE / day.
[0135] Suitably, vitamin A is administered to a subject in an amount of at least about 100 μg RE / day, at least about 200 μg RAE / day, or at least about 300 μg RAE / day. Suitably, vitamin A is administered to a subject in an amount of about 1000 μg RAE / day or less, about 800 μg RAE / day or less, about 600 μg RAE / day or less, or about 400 μg RAE / day or less. Suitably, vitamin A is administered to a subject in an amount of about 100 μg RAE / day to about 1000 μg RAE / day, about 200 μg RAE / day to about 800 μg RAE / day, about 300 μg RAE / day to about 600 μg RAE / day, or about 300 μg RAE / day to about 400 μg RAE / day.
[0136] Vitamin D
[0137] Vitamin D is a group of fat-soluble, open-ring steroids including vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol). Calcitriol (also known as 1,25-dihydroxyvitamin D) is the active form of vitamin D. Suitably, vitamin D comprises or consists of vitamin D2 and vitamin D3. Suitably, vitamin D comprises or consists of calcitriol.
[0138] Any suitable amount of vitamin D may be administered to a subject in any suitable form and by any suitable route of administration (e.g., in any form and by any route described herein). Suitable doses of vitamin D are described, for example, in Greer, FR, 2004. The American journal of clinical nutrition, 80(6), pp. 1759S-1762S and EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2016. EFSA Journal, 14(10), p. e04547.
[0139] Suitably, vitamin D is administered to a subject in an amount of at least about 2.5 μg / day, at least about 5 μg / day, at least about 10 μg / day, or at least about 15 μg / day. Suitably, vitamin D is administered to a subject in an amount of about 100 μg / day or less, about 75 μg / day or less, or about 50 μg / day or less. Suitably, vitamin D is administered to a subject in an amount of about 2.5 μg / day to about 100 μg / day, about 5 μg / day to about 100 μg / day, about 10 μg / day to about 75 μg / day, or about 15 μg / day to about 50 μg / day. Suitably, vitamin D is administered to a subject in an amount of about 15 μg / day.
[0140] Vitamin Mix
[0141] Prebiotics can be administered in combination with vitamin mixtures. Prebiotics and vitamin mixtures can be administered separately, simultaneously or sequentially. In a preferred embodiment, prebiotics and vitamin mixtures are administered simultaneously.
[0142] In one aspect, the present invention provides a combination of a prebiotic agent and a vitamin mixture for use in treating and / or preventing vitamin K2 deficiency in a subject.
[0143] In another aspect, the present invention provides use of a combination of a prebiotic agent and a vitamin mixture in the manufacture of a medicament for treating and / or preventing vitamin K2 deficiency in a subject.
[0144] In another aspect, the present invention provides a method for treating and / or preventing vitamin K2 deficiency in a subject in need thereof, the method comprising administering to the subject an effective amount of a combination of a prebiotic agent and a vitamin mixture.
[0145] In another aspect, the present invention provides the use of a combination of a prebiotic agent and a vitamin mixture for promoting vitamin K2 production in the intestine of a subject.
[0146] As used herein, a "vitamin mixture" may refer to a mixture of two or more vitamins. Any suitable vitamin mixture may be used.
[0147] In some embodiments, the vitamin mixture comprises or consists of vitamin K1, vitamin A, and vitamin D. Suitably, vitamin K1 is administered to the subject in an amount of about 5 μg / day to about 200 μg / day, vitamin A is administered to the subject in an amount of about 100 μg RE / day to about 1000 μg RE / day, and vitamin D is administered to the subject in an amount of about 2.5 μg / day to about 100 μg / day.
[0148] In other embodiments, the vitamin mixture comprises or consists of vitamin K2, vitamin A, and vitamin D. Suitably, vitamin K2 is administered to the subject in an amount of about 5 μg / day to about 200 μg / day, vitamin A is administered to the subject in an amount of about 100 μg RE / day to about 1000 μg RE / day, and vitamin D is administered to the subject in an amount of about 2.5 μg / day to about 100 μg / day.
[0149] In further embodiments, the present invention provides for the use of a combination of a prebiotic agent and vitamin K2 for treating and / or preventing vitamin K2 deficiency in a subject.
[0150] In further embodiments, the present invention provides for the use of a combination of a prebiotic agent and vitamin A for treating and / or preventing vitamin K2 deficiency in a subject.
[0151] In further embodiments, the present invention provides for the use of a combination of a prebiotic agent and vitamin D for treating and / or preventing vitamin K2 deficiency in a subject.
[0152] In further embodiments, the present invention provides the use of a combination of a prebiotic agent and vitamin K2, vitamin A, vitamin D, or any combination thereof for treating and / or preventing vitamin K2 deficiency in a subject.
[0153] Probiotics
[0154] Prebiotics can be administered in combination with one or more probiotics. Prebiotics and one or more probiotics can be administered separately, simultaneously or sequentially. In a preferred embodiment, prebiotics and one or more probiotics are administered simultaneously.
[0155] As used herein, the term "probiotics" may refer to components containing a sufficient number of live microorganisms to change the intestinal microbiota of a subject (see, e.g., Hill, C. et al., 2014. Nature reviews Gastroenterology & hepatology, 11 (8), p. 506). Suitably, probiotics include commercially available probiotic strains and / or strains that have been shown to have health benefits (see, e.g., Fijan, S., 2014, International journal of environmental research and public health, 11 (5), p. 4745-4767). Exemplary probiotic microorganisms can include Bifidobacterium, Lactobacillus, Limosilactobacillus, Lacticaseibacillus, Saccharomyces, Enterococcus, Streptococcus, Pediococcus, Leuconostoc, Bacillus, and Escherichia coli.
[0156] In one aspect, the invention provides a combination of a prebiotic agent and one or more probiotics for use in treating and / or preventing vitamin K2 deficiency in a subject.
[0157] In another aspect, the present invention provides use of a combination of a prebiotic agent and one or more probiotics in the manufacture of a medicament for treating and / or preventing vitamin K2 deficiency in a subject.
[0158] In another aspect, the present invention provides a method for treating and / or preventing vitamin K2 deficiency in a subject in need thereof, the method comprising administering to the subject an effective amount of a combination of a prebiotic agent and one or more probiotics.
[0159] In another aspect, the present invention provides the use of a combination of a prebiotic agent and one or more probiotics for promoting vitamin K2 production in the intestine of a subject.
[0160] In another aspect, the present invention provides a method for promoting vitamin K2 production in the intestine of a subject, the method comprising administering to the subject an effective amount of a combination of a prebiotic agent and one or more probiotics.
[0161] One or more probiotics can increase vitamin K2 production. The inventors surprisingly found that probiotics can promote endogenous production of vitamin K2 through the production of precursors.
[0162] In some embodiments, one or more probiotics include or consist of Lactobacillus paracasei, Bifidobacterium, Lactobacillus and / or Lactobacillus reuteri. In some embodiments, one or more probiotics include or consist of Lactobacillus rhamnosus, Bifidobacterium longum and / or Bifidobacterium animalis.
[0163] Lactobacillus rhamnosus
[0164] In some embodiments, the one or more probiotics comprise or consist of Lactobacillus rhamnosus.
[0165] Lactobacillus rhamnosus (Lactobacillus rhamnosus) is a short, gram-positive, homofermentative, facultative anaerobic, spore-free rod that usually appears in the form of a chain. Lactobacillus rhamnosus GG (LGG) is one of the most widely used probiotic strains. Various health effects have been documented (see, e.g., Segers, ME and Lebeer, S., 2014. Microbial cell factories, 13 (1), pp. 1-16). Lactobacillus rhamnosus can promote the endogenous production of vitamin K2 through the production of precursors.
[0166] In some embodiments, the one or more probiotics comprise or consist of Lactobacillus rhamnosus LPR.
[0167] Bifidobacterium longum
[0168] In some embodiments, the one or more probiotics comprise or consist of Bifidobacterium longum.
[0169] Bifidobacterium longum is a bacterium found in the human digestive tract. In 2002, three previously distinct species of Bifidobacterium (B. infantis, B. longum and B. suis) were merged into a single species named Bifidobacterium longum with the biotypes B. infantis, B. longum and B. suis, respectively (Sakata, S. et al., 2002. International journal of systematic and evolutionary microbiology, 52(6), pp. 1945-1951).
[0170] In some embodiments, the one or more probiotics comprise or consist of Bifidobacterium longum ssp. infantis (also known as Bifidobacterium infantis), Bifidobacterium longum ssp. suis (also known as Bifidobacterium suis) and / or Bifidobacterium longum ssp. longum (also known as Bifidobacterium longum).
[0171] In some embodiments, the one or more probiotics include or consist of Bifidobacterium infantis. In some embodiments, the one or more probiotics include or consist of Bifidobacterium infantis LMG 11588 or a derivative thereof (e.g., R0033, which has been deemed safe (GRAS) by the US Food and Drug Administration, see, e.g., Duboux, S. et al., 2022. Microorganisms, 10 (2), p. 203). Bifidobacterium infantis can promote endogenous production of vitamin K2 by the production of precursors.
[0172] Bifidobacterium animalis
[0173] In some embodiments, the one or more probiotics comprise or consist of Bifidobacterium animalis.
[0174] Bifidobacterium animalis a bacterium of the genus Bifidobacterium that can be found in the large intestine of most mammals, including humans. Bifidobacterium animalis and Bifidobacterium lactis were previously described as two different species. Currently, both are considered, namely Bifidobacterium animalis with subspecies Bifidobacterium animalis subspecies and Bifidobacterium animalis subspecies lactis (see Masco, L. et al., 2004. International Journal of Systematic and Evolutionary Microbiology, 54 (4), pp. 1137-1143).
[0175] In some embodiments, the one or more probiotics comprise or consist of Bifidobacterium animalis lactis (also known as Bifidobacterium lactis). For example, the bacterium Bifidobacterium lactis HN019 has been studied for a variety of traits important for its ability to function as a probiotic (see, e.g., Sanders, ME, 2006. Journal of clinical gastroenterology, 40(9), pp. 776-783).
[0176] Administration of probiotics
[0177] The probiotics may be administered to a subject in any suitable amount, in any suitable form and by any suitable route of administration (eg, in any form and by any route described herein).
[0178] Suitably, the one or more probiotics are present in an amount of at least about 10 5 cfu / day, at least about 10 6 cfu / day, at least about 10 7 cfu / day, at least about 10 8 cfu / day, at least about 10 9 cfu / day or at least about 10 10 cfu / day is administered to the subject. Suitably, the one or more probiotics are administered in an amount of about 10 12 cfu / day or less, about 10 11 cfu / day or less or about 10 10 cfu / day or less. Suitably, the one or more probiotics are administered to the subject in an amount of about 10 6 cfu / day to about 10 12 cfu / day, about 10 7 cfu / day to about 10 11 cfu / day or about 10 8 cfu / day to about 10 10 A total amount of 10 cfu / day was administered to the subjects.
[0179] Suitably, the Lactobacillus rhamnosus is present in an amount of at least about 10 5 cfu / day, at least about 10 6 cfu / day, at least about 10 7 cfu / day, at least about 10 8 cfu / day, at least about 10 9 cfu / day or at least about 10 10 cfu / day is administered to a subject. Suitably, the Lactobacillus rhamnosus is administered at about 10 12 cfu / day or less, about 10 11 cfu / day or less or about 10 10 cfu / day or less. Suitably, the Lactobacillus rhamnosus is administered to a subject at about 10 6 cfu / day to about 10 12 cfu / day, about 10 7 cfu / day to about 10 11 cfu / day or about 10 8 cfu / day to about 10 10 cfu / day were administered to the subjects.
[0180] Suitably, Bifidobacterium longum (eg, Bifidobacterium infantis) is present in an amount of at least about 10 5 cfu / day, at least about 10 6 cfu / day, at least about 10 7 cfu / day, at least about 10 8 cfu / day, at least about 10 9 cfu / day or at least about 10 10 cfu / day is administered to a subject. Suitably, Bifidobacterium longum (e.g., Bifidobacterium infantis) is administered at about 10 12 cfu / day or less, about 10 11 cfu / day or less or about 10 10 cfu / day or less. Suitably, Bifidobacterium longum (e.g., Bifidobacterium infantis) is administered to a subject in an amount of about 10 6 cfu / day to about 10 12 cfu / day, about 10 7 cfu / day to about 10 11 cfu / day or about 10 8 cfu / day to about 10 10 cfu / day were administered to the subjects.
[0181] Suitably, the animal Bifidobacterium (e.g., Bifidobacterium lactis) is present in an amount of at least about 10 5 cfu / day, at least about 10 6 cfu / day, at least about 10 7 cfu / day, at least about 108 cfu / day, at least about 10 9 cfu / day or at least about 10 10 cfu / day is administered to a subject. Suitably, animal Bifidobacterium (e.g., Bifidobacterium lactis) is administered at about 10 12 cfu / day or less, about 10 11 cfu / day or less or about 10 10 cfu / day or less. Suitably, animal Bifidobacterium (e.g., Bifidobacterium lactis) is administered to a subject in an amount of about 10 6 cfu / day to about 10 12 cfu / day, about 10 7 cfu / day to about 10 11 cfu / day or about 10 8 cfu / day to about 10 10 cfu / day were administered to the subjects.
[0182] Suitably, the prebiotic agent is administered to the subject in an amount of about 0.5 g / day to about 10 g / day, and the one or more probiotics are administered to the subject in an amount of about 10 6 cfu / day to about 10 12 A total amount of 10 cfu / day was administered to the subjects.
[0183] Suitably, the prebiotic agent is administered to the subject in an amount of about 0.5 g / day to about 10 g / day, vitamin K1 is administered to the subject in an amount of about 5 μg / day to about 200 μg / day, and one or more probiotics are administered to the subject in an amount of about 10 6 cfu / day to about 10 12 A total amount of 10 cfu / day was administered to the subjects.
[0184] Composition
[0185] Suitably, the prebiotic agent (or combination therewith) is in the form of a composition.The composition may comprise any therapeutically effective amount of the combination.
[0186] The composition can be any type of composition that can be incorporated into the combination, such as a food or beverage product, an animal feed product, a nutritional supplement for humans or animals, or a composition in the form of a pharmaceutical composition. The composition can be in solid (e.g., powder), liquid, or semi-liquid form. The combination can be in the form of a food composition, a pet food composition, a beverage, a nutritional formula, a nutritional supplement, or a nutraceutical.
[0187] Food and beverage products include all products intended to be consumed orally by humans for the purpose of providing nutrition and / or pleasure. For example, it can be a nutritional composition, such as for young children. Examples of food and beverage products include dairy products, such as dairy products or yogurt, soups, sauces, sweet and salty snacks, powdered beverages and cereal products.
[0188] In some embodiments, a prebiotic agent (or combination therewith) is in the form of a nutritional composition, a medical food product for clinical nutrition, or a supplement.
[0189] In some embodiments, the prebiotic agent (or combination thereof) is in the form of a nutritional composition. As used herein, "nutritional composition" may mean a composition that provides nutrients to a subject. Such nutritional compositions are typically administered orally or intravenously, and typically include a lipid or fat source and a protein source.
[0190] In some embodiments, the prebiotic agent (or combination thereof) is in the form of a medical food product for clinical nutrition. As used herein, "medical food products for clinical nutrition" may also be referred to as "foods for special medical purposes (FSMP)", and refer to specialized foods designed to help meet the nutritional or dietary needs of subjects with a disease, disorder, or medical condition who are temporarily or permanently unable to obtain adequate nutritional intake from normal foods or by modifying their normal diet.
[0191] In some embodiments, the prebiotic agent (or combination thereof) is in the form of an infant formula. In this case, the infant formula can be a premature infant formula, a human milk fortifier, a starter formula, an older infant formula, a toddler food formula, an infant cereal formula, or a growing-up milk.
[0192] In some embodiments, the prebiotic agent (or combination thereof) is in the form of a growing-up milk. As used herein, the term "growing-up milk" (or GUM) refers to a milk formula food product provided after one year. It is typically a dairy-based beverage suitable for the specific nutritional needs of a toddler (e.g., a child from about 1 to about 3 years old). Growing-up milk may also be referred to as a "toddler formula" or "toddler milk".
[0193] In some embodiments, the prebiotic agent (or combination thereof) is in the form of a milk formula. As used herein, the term "milk formula" may refer to a food intended for, for example, childhood nutrition, which may provide a sole source or supplemental nutrition for, for example, a child about 3 years old or older. In some embodiments, the milk formula is a growing-up milk.
[0194] In some embodiments, the composition is in powder form and is reconstituted in an aqueous medium (e.g., water) prior to administration. In other embodiments, the composition is in liquid form ready for administration (e.g., a ready-to-feed formula).
[0195] In another embodiment, the prebiotic agent (or combination thereof) is in the form of a supplement. As used herein, a "supplement" or "dietary supplement" can be used to supplement the nutrition of a subject (it is usually used as such, but it can also be added to any type of composition intended to be ingested by a subject). When the composition is a supplement, it can be provided in unit dosage form. Supplements are usually in the form of liquids, gels, powders, or tablets or capsules. Powder supplements generally encompass supplements to be dissolved in water or milk or sprayed on food or beverages. Such supplements are intended to provide additional nutrition and / or health benefits to the subject who consumes it. Supplements can be used to provide nutrients and / or health benefits to humans as well as animals.
[0196] In another embodiment, the prebiotic agent (or combination therewith) is in the form of a fortifier. The fortifier may be an infant formula fortifier or a growing-up milk fortifier.
[0197] In another embodiment, the prebiotic agent (or combination therewith) is in the form of a pharmaceutical product. Pharmaceutical products include, for example, drops, syrups, powders, tablets or capsule products intended to treat or prevent an adverse medical condition in an individual in need thereof.
[0198] Prebiotic agents (or combinations thereof) can also be in the form of animal food products or nutritional supplements for animals. Preferably, the animal is a mammal. Examples of animals include primates (e.g., humans), cattle, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds, etc.
[0199] Prebiotics
[0200] The nutritional composition according to the invention may contain any suitable amount of a prebiotic agent.
[0201] Suitably, the nutritional composition comprises a total amount of prebiotic agent of at least about 0.5 wt%, at least about 1 wt%, at least about 2 wt%, at least about 3 wt%, at least about 4 wt%, or at least about 5 wt% on a dry weight basis. Suitably, the nutritional composition comprises a total amount of prebiotic agent of about 10 wt% or less, about 8 wt% or less, or about 5 wt% or less on a dry weight basis. Suitably, the nutritional composition comprises a total amount of prebiotic agent of about 0.5 wt% to about 10 wt%, about 1 wt% to about 8 wt%, or about 2 wt% to about 5 wt% on a dry weight basis.
[0202] Suitably, the prebiotic agent comprises BMO in an amount of about 80% to about 100% by weight relative to the total weight of the prebiotic agent. Suitably, the nutritional composition comprises a total amount of BMO of at least about 0.5%, at least about 1%, at least about 2%, at least about 3%, at least about 4%, or at least about 5% by weight based on dry weight. Suitably, the nutritional composition comprises a total amount of BMO of about 10% or less, about 8% or less, or about 5% or less by weight based on dry weight. Suitably, the nutritional composition comprises a total amount of BMO of about 0.5% to about 10%, about 1% to about 8%, or about 2% to about 5% by weight based on dry weight.
[0203] Suitably, the nutritional composition comprises a total amount of HMO of at least about 0.5 wt %, at least about 1 wt %, at least about 2 wt %, at least about 3 wt %, at least about 4 wt % or at least about 5 wt % on a dry weight basis. Suitably, the nutritional composition comprises a total amount of HMO of about 10 wt % or less, about 8 wt % or less or about 5 wt % or less on a dry weight basis. Suitably, the nutritional composition comprises a total amount of HMO of about 0.5 wt % to about 10 wt %, about 1 wt % to about 8 wt % or about 2 wt % to about 5 wt % on a dry weight basis.
[0204] Suitably, the nutritional composition comprises at least one fucosylated oligosaccharide in an amount of about 0.05% to about 3% by weight, about 0.1% to about 2% by weight, or about 0.2% to about 1.5% by weight based on dry weight. Suitably, the nutritional composition comprises at least one sialylated oligosaccharide in an amount of about 0.01% to about 2% by weight, about 0.05% to about 1.5% by weight, or about 0.07% to about 1% by weight based on dry weight. Suitably, the nutritional composition comprises at least one N-acetylated oligosaccharide in an amount of about 0.01% to about 1% by weight, about 0.03% to about 0.6% by weight, or about 0.05% to about 0.5% by weight based on dry weight.
[0205] Suitably, the nutritional composition comprises a total amount of 2'FL of about 0.05 g / L to about 2 g / L, about 0.1 g / L to about 1 g / L, about 0.15 g / L to about 0.8 g / L, about 0.2 g / L to about 0.7 g / L, or about 0.25 g / L to about 0.6 g / L (the concentration may refer to the concentration of the composition after reconstitution, e.g., with water).
[0206] Suitably, the nutritional composition comprises a total amount of fucosylated oligosaccharides (e.g., 2'FL and / or diFL) of about 0.1 g / L to about 4 g / L, about 0.1 g / L to about 3.5 g / L, about 0.15 g / L to about 3 g / L, about 0.2 g / L to about 2.5 g / L, about 0.3 g / L to about 2 g / L, about 0.4 g / L to about 2 g / L, or about 0.5 g / L to about 2 g / L (the concentration may refer to the concentration of the composition after reconstitution, e.g., with water). In a specific embodiment, the nutritional composition comprises about 0.2 g / L to about 1.8 g / L of total fucosylated oligosaccharides.
[0207] Suitably, the nutritional composition comprises a total amount of sialylated oligosaccharides (e.g., 3'-sialyllactose (3'-SL) and / or 6'-sialyllactose (6'-SL)) of about 0.05 g / L to about 0.75 g / L, about 0.05 g / L to about 0.5 g / L, about 0.1 g / L to about 0.3 g / L, or about 0.1 g / L to about 0.4 g / L (the concentration may refer to the concentration after the composition has been reconstituted, e.g., with water). In a specific embodiment, the nutritional composition comprises about 0.12 g / L to about 0.4 g / L total sialylated oligosaccharides.
[0208] Suitably, the nutritional composition comprises a total amount of N-acetylated oligosaccharides (e.g., LNT and / or LNnT) of about 0.05 g / L to about 0.5 g / L, about 0.1 g / L to about 0.5 g / L, about 0.2 g / L to about 0.4 g / L or about 0.3 g / L (the concentration may refer to the concentration of the composition after reconstitution, e.g., with water).
[0209] Suitably, the nutritional composition comprises:
[0210] - a total amount of about 0.05 g / L to about 0.75 g / L, about 0.05 g / L to about 0.5 g / L, about 0.1 g / L to about 0.3 g / L, or about 0.1 g / L to about 0.4 mg / L of at least one sialylated oligosaccharide;
[0211] - a total amount of at least one fucosylated oligosaccharide from about 0.1 g / L to about 4 g / L, from about 0.1 g / L to about 3.5 g / L, from about 0.15 g / L to about 3 g / L, from about 0.2 g / L to about 2.5 g / L, from about 0.3 g / L to about 2 g / L, from about 0.4 g / L to about 2 g / L, or from about 0.5 g / L to about 2 g / L; and / or
[0212] - a total amount of about 0.05 g / L to about 0.5 g / L, about 0.1 g / L to about 0.5 g / L, or about 0.2 g / L to about 0.4 g / L of at least one N-acetylated oligosaccharide.
[0213] Suitably, the nutritional composition comprises COS in an amount of at least about 0.5 wt %, at least about 1 wt %, at least about 2 wt %, at least about 3 wt %, at least about 4 wt %, or at least about 5 wt % on a dry weight basis. Suitably, the nutritional composition comprises COS in an amount of about 10 wt % or less, about 8 wt % or less, or about 5 wt % or less on a dry weight basis. Suitably, the nutritional composition comprises COS in an amount of about 0.5 wt % to about 10 wt %, about 1 wt % to about 8 wt %, or about 2 wt % to about 5 wt % on a dry weight basis.
[0214] Vitamins
[0215] The nutritional composition according to the invention may contain any suitable amounts of vitamins.
[0216] Suitably, the nutritional composition comprises vitamin K1 in an amount of at least about 5 μg / 100g, at least about 10 μg / 100g, at least about 15 μg / 100g, at least about 20 μg / 100g, at least about 25 μg / 100g, or at least about 30 μg / 100g based on dry weight. Suitably, the nutritional composition comprises vitamin K1 in an amount of about 2100 μg / 100g or less, about 100 μg / 100g or less, about 90 μg / 100g or less, about 80 μg / 100g or less, about 70 μg / 100g or less, or about 60 μg / 100g or less based on dry weight. Suitably, the nutritional composition comprises vitamin K1 in an amount of about 5 μg / 100g to about 200 μg / 100g, about 10 μg / 100g to about 100 μg / 100g, about 15 μg / 100g to about 90 μg / 100g, about 20 μg / 100g to about 80 μg / 100g, about 25 μg / 100g to about 70 μg / 100g or about 30 μg / 100g to about 60 μg / 100g.
[0217] Suitably, the nutritional composition comprises vitamin K2 in an amount of at least about 5 μg / 100g, at least about 10 μg / 100g, at least about 15 μg / 100g, at least about 20 μg / 100g, at least about 25 μg / 100g, or at least about 30 μg / 100g on a dry weight basis. Suitably, the nutritional composition comprises vitamin K2 in an amount of about 2100 μg / 100g or less, about 100 μg / 100g or less, about 90 μg / 100g or less, about 80 μg / 100g or less, about 70 μg / 100g or less, or about 60 μg / 100g or less on a dry weight basis. Suitably, the nutritional composition comprises vitamin K2 in an amount from about 5 μg / 100g to about 200 μg / 100g, from about 10 μg / 100g to about 100 μg / 100g, from about 15 μg / 100g to about 90 μg / 100g, from about 20 μg / 100g to about 80 μg / 100g, from about 25 μg / 100g to about 70 μg / 100g or from about 30 μg / 100g to about 60 μg / 100g.
[0218] Suitably, the nutritional composition comprises vitamin A in an amount of at least about 100 μg RE / 100 g, at least about 200 μg RE / 100 g, or at least about 300 μg RE / 100 g on a dry weight basis. Suitably, the nutritional composition comprises vitamin A in an amount of about 1000 μg RE / 100 g or less, about 800 μg RE / 100 g or less, about 600 μg RE / 100 g or less, or about 400 μg RE / 100 g or less on a dry weight basis. Suitably, the nutritional composition comprises vitamin A in an amount of about 100 μg RE / 100g to about 1000 μg RE / 100g, about 200 μg RE / 100g to about 800 μg RE / 100g, about 300 μg RE / 100g to about 600 μg RE / 100g or about 300 μg RE / 100g to about 400 μg RE / 100g on a dry weight basis.
[0219] Suitably, the nutritional composition comprises vitamin A in an amount of at least about 100 μg RAE / 100 g, at least about 200 μg RAE / 100 g, or at least about 300 μg RAE / 100 g on a dry weight basis. Suitably, the nutritional composition comprises vitamin A in an amount of about 1000 μg RAE / 100 g or less, about 800 μg RAE / 100 g or less, about 600 μg RAE / 100 g or less, or about 400 μg RAE / 100 g or less on a dry weight basis. Suitably, the nutritional composition comprises vitamin A in an amount from about 100 μg RAE / 100g to about 1000 μg RAE / 100g, from about 200 μg RAE / 100g to about 800 μg RAE / 100g, from about 300 μg RAE / 100g to about 600 μg RAE / 100g or from about 300 μg RAE / 100g to about 400 μg RAE / 100g on a dry weight basis.
[0220] Suitably, the nutritional composition comprises vitamin D in an amount of at least about 5 μg / 100g, at least about 10 μg / 100g or at least about 15 μg / 100g on a dry weight basis. Suitably, the nutritional composition comprises vitamin D in an amount of about 100 μg / 100g or less, about 75 μg / 100g or less or about 50 μg / 100g or less on a dry weight basis. Suitably, the nutritional composition comprises vitamin D in an amount of about 5 μg / 100g to about 100 μg / 100g, about 10 μg / 100g to about 75 μg / 100g or about 15 μg / 100g to about 50 μg / 100g on a dry weight basis.
[0221] Probiotics
[0222] The nutritional composition according to the invention may contain any suitable amount of probiotics.
[0223] Suitably, the nutritional composition comprises, on a dry weight basis, at least about 10 5 cfu / 100g, at least about 10 6 cfu / 100g, at least about 10 7 cfu / 100g or at least about 10 8 cfu / 100g, at least about 10 9 cfu / 100g or at least about 10 10 cfu / 100g of one or more probiotics. Suitably, the nutritional composition comprises about 10 12 cfu / 100g or less, about 10 11 cfu / 100g or less, about 10 10 cfu / 100g or less of one or more probiotics. Suitably, the nutritional composition comprises about 106 cfu / 100g to about 10 12 cfu / 100g, about 10 7 cfu / 100g to about 10 11 cfu / 100g or about 10 8 cfu / 100g to about 10 10 cfu / 100g of total amount of one or more probiotics.
[0224] Suitably, the nutritional composition comprises, on a dry weight basis, at least about 10 5 cfu / 100g, at least about 10 6 cfu / 100g, at least about 10 7 cfu / 100g or at least about 10 8 cfu / 100g, at least about 10 9 cfu / 100g or at least about 10 10 cfu / 100g of Bifidobacterium longum (e.g. Bifidobacterium infantis). Suitably, the nutritional composition comprises about 10 cfu / 100g on a dry weight basis. 12 cfu / 100g or less, about 10 11 cfu / 100g or less, about 10 10 cfu / 100g or less of Bifidobacterium longum (e.g. Bifidobacterium infantis). Suitably, the nutritional composition comprises about 10 6 cfu / 100g to about 10 12 cfu / 100g, about 10 7 cfu / 100g to about 10 11 cfu / 100g or about 10 8 cfu / 100g to about 10 10 cfu / 100g.
[0225] Suitably, the nutritional composition comprises, on a dry weight basis, at least about 10 5 cfu / 100g, at least about 10 6 cfu / 100g, at least about 10 7 cfu / 100g or at least about 10 8 cfu / 100g, at least about 10 9 cfu / 100g or at least about 10 10 cfu / 100g of animal Bifidobacterium (e.g., Bifidobacterium lactis). Suitably, the nutritional composition comprises about 10 cfu / 100g on a dry basis. 12 cfu / 100g or less, about 10 11 cfu / 100g or less, about 10 10cfu / 100g or less. Suitably, the nutritional composition comprises about 10 6 cfu / 100g to about 10 12 cfu / 100g, about 10 7 cfu / 100g to about 10 11 cfu / 100g or about 10 8 cfu / 100g to about 10 10 Animal Bifidobacterium (eg Bifidobacterium lactis) in an amount of cfu / 100g.
[0226] Suitably, the nutritional composition comprises, on a dry weight basis, at least about 10 5 cfu / 100g, at least about 10 6 cfu / 100g, at least about 10 7 cfu / 100g or at least about 10 8 cfu / 100g, at least about 10 9 cfu / 100g or at least about 10 10 cfu / 100g of Lactobacillus rhamnosus. Suitably, the nutritional composition comprises about 10 cfu / 100g on a dry basis. 12 cfu / 100g or less, about 10 11 cfu / 100g or less, about 10 10 cfu / 100g or less. Suitably, the nutritional composition comprises about 10 6 cfu / 100g to about 10 12 cfu / 100g, about 10 7 cfu / 100g to about 10 11 cfu / 100g or about 10 8 cfu / 100g to about 10 10 cfu / 100g of Lactobacillus rhamnosus.
[0227] Other components
[0228] The nutritional composition of the present invention may contain a protein source, a carbohydrate source and a lipid source. However, in some embodiments, particularly if the nutritional composition of the present invention is a supplement or fortifier, only lipids (or a lipid source) may be present.
[0229] The nutritional composition of the present invention may comprise from about 100 kcal / 100 g to about 1000 kcal / 100 g, from about 200 kcal / 100 g to about 800 kcal / 100 g, or from about 400 kcal / 100 g to about 600 kcal / 100 g on a dry weight basis.
[0230] protein
[0231] The nutritional composition according to the present invention may contain a protein source. The amount of protein may be from about 1 g to about 4 g / 100 kcal or from about 1.5 g to about 3 g / 100 kcal.
[0232] Protein sources based on, for example, whey, casein and mixtures thereof can be used, as well as plant-based (e.g., soy-based) protein sources. With regard to the whey protein of interest, the protein source can be based on acid whey or sweet whey or a mixture thereof, and can contain alpha-lactalbumin and beta-lactoglobulin in any desired proportion. In some embodiments, the protein source is mainly whey (i.e., more than 50% of the protein comes from whey protein, such as 60%> or 70%>). The protein can be intact or hydrolyzed, or a mixture of intact protein and hydrolyzed protein. The so-called term "intact" means that the main part of the protein is intact, i.e., the molecular structure has not changed, for example, at least 80% of the protein has not changed, such as at least 85% of the protein has not changed, preferably at least 90% of the protein has not changed, even more preferably at least 95% of the protein has not changed, such as at least 98% of the protein has not changed. In a specific embodiment, 100% of the protein has not changed.
[0233] The term "hydrolyzed" means in the context of the present invention that a protein has been hydrolyzed or broken down into its constituent amino acids.
[0234] The protein may be fully hydrolyzed or partially hydrolyzed. If hydrolyzed protein is desired, a hydrolysis process may be performed as desired and as known in the art. For example, a whey protein hydrolyzate may be prepared by enzymatic hydrolysis of the whey fraction in one or more steps. If the whey fraction used as a raw material is substantially lactose-free, it is found that the protein undergoes much less lysine blockage during the hydrolysis process. This makes it possible to reduce the degree of lysine blockage from about 15% by weight of total lysine to less than about 10% by weight of lysine; for example, about 7% by weight of lysine, which greatly improves the nutritional quality of the protein source.
[0235] In a specific embodiment, the protein of the composition is hydrolyzed, fully hydrolyzed or partially hydrolyzed. The degree of hydrolysis (DH) of the protein may be 2 to 20, 8 to 40, or 20 to 60, or 20 to 80, or greater than 10, 20, 40, 60, 80 or 90.
[0236] At least 70%, 80%, 85%, 90%, 95% or 97% of the protein may be hydrolyzed. In a particular embodiment, 100% of the protein is hydrolyzed.
[0237] In a specific embodiment, the protein of the composition is a plant-based protein.
[0238] carbohydrate
[0239] The nutritional composition according to the present invention may contain a carbohydrate source. The amount of carbohydrate may be from about 5 g to about 20 g / 100 kcal or from about 10 g to about 15 g / 100 kcal.
[0240] Any carbohydrate source conventionally found in nutritional compositions may be used, such as lactose, sucrose (saccharose), maltodextrin, starch and mixtures thereof, but the preferred carbohydrate source is lactose.
[0241] Lipids
[0242] The nutritional composition according to the present invention may contain lipids and essential fatty acids. The amount of lipids may be from about 1 g to about 10 g / 100 kcal or from about 2 g to about 6 g / 100 kcal.
[0243] Non-limiting examples of lipids include: palm olein, high oleic sunflower oil, high oleic safflower oil, canola oil, fish oil, coconut oil, milk fat and combinations thereof. It may be particularly beneficial if the composition comprises fat in an amount of about 25 to about 30 g / 100 g of the dry weight of the composition. Non-limiting examples of essential fatty acids include: linoleic acid (LA), alpha-linolenic acid (ALA). The composition of the present invention may also contain gangliosides, monosialoganglioside-3 (GM3) and disialoganglioside 3 (GD3) and combinations thereof.
[0244] Other components
[0245] The nutritional composition of the present invention may also contain all vitamins and minerals that are considered to be necessary for daily diet and in significant amounts of nutrition. The minimum requirements of certain vitamins and minerals have been determined. Examples of minerals, vitamins and other nutrients optionally present in the composition of the present invention include vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B12, vitamin E, vitamin C, folic acid, inositol, niacin, biotin, pantothenic acid, choline, calcium, phosphorus, iodine, iron, magnesium, copper, zinc, manganese, chlorine, potassium, sodium, selenium, chromium, molybdenum, taurine and L-carnitine. Minerals are usually added in the form of salts. The presence and amount of specific minerals and other vitamins will vary according to the target group. If necessary, the nutritional composition of the present invention may contain emulsifiers and stabilizers, such as soybeans, lecithin, citric acid monoglyceride and citric acid diglyceride, etc.
[0246] The nutritional composition of the present invention may also contain other substances that may have a beneficial effect, especially on bone health or bone development, such as lactoferrin, osteopontin, TGFbeta, slgA, glutamine, nucleotides, nucleosides, etc.
[0247] Preparation of composition
[0248] The composition according to the present invention may be prepared by any known or other suitable means. For example, the nutritional composition may be completed by blending a protein source with a carbohydrate source and a lipid source in suitable proportions. If an emulsifier is used, it may be included at this stage. Vitamins and minerals may be added at this stage, but may also be added later to avoid thermal degradation. Water (preferably reverse osmosis water or deionized water) may then be added and mixed in to form a liquid mixture. The mixing temperature is preferably room temperature, but may also be higher. The liquid mixture may then be heat treated to reduce the bacterial load. The mixture may then be homogenized.
[0249] If it is desired to produce a powdered composition, the homogenized mixture is dried in a suitable drying apparatus, such as a spray dryer or a freeze dryer, and converted into a powder.
[0250] The method for making formula food is based on the concept that the product must be nutritionally adequate and safe to eat in terms of microbiology. Therefore, the step of eliminating or limiting microbial growth is essential for the production method. The processing technology of each specific formula food belongs to the manufacturer, but generally speaking, for powder products, it involves preserving oil-in-water (o / w) emulsions by dehydration, or for ready-to-eat or concentrated liquid products, it involves sterilization. Powdered formula food can be produced by various methods, such as dry mixing of dehydrated ingredients to form a uniform formula food, or hydrating and wet mixing of a mixture of constant ingredients (such as fat, protein and carbohydrate ingredients), and then evaporating the resulting mixture and spray drying. A combination of the above two methods can be used, wherein a basic powder is first prepared by wet mixing and spray drying of all or some constant ingredients, and then dry mixing of the remaining ingredients (including carbohydrates, minerals and vitamins and other trace nutrients) to obtain the final formula food. Liquid formula food is provided in ready-to-eat form or as a concentrated liquid, the latter needs to be diluted with water, usually 1: 1. The manufacturing methods for these products are similar to those used to make reconstituted milk.
[0251] If it is desired to produce a liquid formula, the homogenised mixture can be filled into suitable containers, preferably under aseptic conditions. However, the liquid composition can also be cooked in the container, and suitable equipment for such filling and cooking is commercially available.
[0252] Subjects
[0253] The subject can be any suitable subject. Suitably, the subject can be a mammal. In preferred embodiments, the subject is a human. In other embodiments, the subject is an animal, preferably wherein the animal is a pet. The pet can be an animal selected from dogs, cats, birds, fish, rodents (such as mice, rats and guinea pigs, rabbits), etc. In some embodiments, the pet is a dog. In some embodiments, the pet is a small dog breed.
[0254] In some embodiments, the subject is a teenager. The term "juvenile" may refer to an individual who has not yet reached adulthood. In some embodiments, the subject is a teenager or a child. The term "teenager" may refer to an individual from the beginning of puberty to adulthood. The term "child" may refer to an individual between the birth stage and puberty.
[0255] In some embodiments, the subject is an infant, a toddler or a young child. The term "infant" may refer to a subject whose age is about 0 to about 1 year old. The term "toddler" may refer to a subject whose age is about 1 to about 3 years old. The term "young child" may refer to a subject whose age is about 3 to about 10 years old, about 3 to about 9 years old, about 3 to about 8 years old, about 3 to about 7 years old, about 3 to about 6 years old, or about 3 to about 5 years old.
[0256] In some embodiments, the subject is a newborn. Newborns typically have low vitamin K and may be at risk of bleeding from vitamin K deficiency (see, e.g., Araki, S. and Shirahata, A., 2020. Nutrients, 12 (3), p. 780). In some embodiments, the subject is a neonate.
[0257] In some embodiments, the age of the subject is about 5 years old or less, about 4 years old or less, about 3 years old or less, about 2 years old or less, or about 1 year old or less. In some embodiments, the age of the subject is about 12 months or less, about 11 months or less, about 10 months or less, about 9 months or less, about 8 months or less, about 7 months or less, or about 6 months or less. In some embodiments, the age of the subject is about 0.5 months or more. In some embodiments, the age of the subject is about 0.5 months to about 6 months.
[0258] In some embodiments, the subject is a teenager or an adult. In some embodiments, the subject is an adult. In some embodiments, the subject is an elderly person. In some embodiments, the subject is at least 60 years old, at least 65 years old, at least 70 years old, at least 75 years old, or at least 80 years old.
[0259] The subject may have or may be at risk for vitamin K2 deficiency. The subject may have or may be at risk for primary vitamin K2 deficiency (i.e., insufficient consumption of vitamin K2). The subject may have or may be at risk for secondary vitamin K2 deficiency. Secondary deficiency can occur in people who consume adequate amounts but have a malabsorption condition (such as cystic fibrosis or chronic pancreatitis), and in people with liver damage or liver disease. Secondary vitamin K deficiency can also occur in people who have a prescription for vitamin K antagonist medications. Long-term antibiotic use and long-term glucocorticoid use can also affect vitamin K levels, especially in children (see, e.g., -Kozakowska, A. and Maresz, K., 2022. Children, 9(1), p. 78).
[0260] In some embodiments, the subject has or is at risk of developing dyslipidemia, diabetes, thalassemia major (TM), cystic fibrosis (CF), inflammatory bowel disease (IBD), or liver disease.
[0261] In some embodiments, the subject has cystic fibrosis, inflammatory bowel disease (eg, Crohn's Disease or ulcerative colitis), liver disease (eg, chronic liver disease), chronic antibiotic use, or chronic glucocorticoid use.
[0262] The subject may have or may be at risk for reduced bone growth and / or bone strength. Vitamin K is required for the gamma-carboxylation of osteocalcin in bone and may be required for the formation of strong bones (see, e.g., Hamidi, MS et al., Journal of clinical densitometry, 16(4), pp. 409-413).
[0263] The present invention is applicable to children who are born prematurely or have low birth weight or experience intrauterine growth retardation, or infants and young children who suffer growth retardation due to malnutrition or experience diseases (such as Crohn's disease and / or celiac disease and / or cancer), or infants and young children treated with drugs (such as chemotherapeutic drugs and / or corticosteroids) that cause malabsorption, anorexia and / or metabolic bone diseases. In some embodiments, the subject is born prematurely or has low birth weight or experiences intrauterine growth retardation, or suffers from intrauterine malnutrition or suffers from developmental retardation. The present invention is also applicable to subjects who are at risk for bone disease, have a family history of bone disease, or have experienced at least one, preferably several, fracture episodes.
[0264] In some embodiments, the subject suffers and / or is suffering from growth retardation. Growth retardation can be defined as a "height for age" value less than two standard deviations of the median value of the WHO Child Growth Standards (see, e.g., De Onis, M. and Branca, F., 2016. Maternal & child nutrition, 12, pp. 12-26).
[0265] In some embodiments, the subject suffers and / or is suffering from growth retardation. The term "growth retardation" can describe a slower weight gain pattern than expected for age and gender in children and other adolescents (see, e.g., King, C. and Davis, T., 2010. European journal of clinical nutrition, 64 (1), pages S11-S13). In some embodiments, the subject suffers and / or is suffering from growth retardation and / or growth retardation due to malnutrition or experiencing diseases such as anorexia, Crohn's disease and / or celiac disease. In some embodiments, the subject suffers and / or is suffering from growth retardation and / or growth retardation due to treatment with drugs (such as chemotherapeutic drugs and / or corticosteroids) that cause malabsorption, anorexia and / or metabolic bone diseases.
[0266] In some embodiments, the subject is premature or has a low birth weight or experiences intrauterine growth retardation. The term "preterm infant" may refer to an infant whose gestational age is less than 37 weeks at birth. The term "low birth weight infant" may refer to an infant whose live birth weight is less than 2,500 g.
[0267] Possible factors that induce vitamin K deficiency in newborns include poor placental transfer of the vitamin, immature intestinal flora, low vitamin K content in breast milk and significant variability between individuals, poor intestinal absorption of vitamin K, and low activity of vitamin K epoxide reductase (see, for example, Araki, S. and Shirahata, A., 2020. Nutrients, 12(3), p. 780).
[0268] Methods for treating and / or preventing vitamin K2 deficiency
[0269] Prebiotic agents (or combinations thereof) may be used to treat and / or prevent vitamin K2 deficiency.
[0270] In one aspect, the present invention provides a prebiotic agent for use in treating and / or preventing vitamin K2 deficiency in a subject.
[0271] In another aspect, the present invention provides use of a prebiotic agent in the manufacture of a medicament for treating and / or preventing vitamin K2 deficiency in a subject.
[0272] In another aspect, the present invention provides a method for treating and / or preventing vitamin K2 deficiency in a subject in need thereof, the method comprising administering to the subject an effective amount of a prebiotic agent.
[0273] The inventors surprisingly found that vitamin K2 production in the gastrointestinal tract (e.g., by conversion of vitamin K1) is promoted by prebiotic agents, such as bovine milk oligosaccharides (BMO), human milk oligosaccharides (HMO) and / or cellooligosaccharides (COS). Prebiotic agents (or combinations thereof) can treat and / or prevent vitamin K2 deficiency by promoting vitamin K2 production in the intestine of a subject. For example, prebiotic agents can treat and / or prevent vitamin K2 deficiency by promoting the de novo production of menaquinone-7 and / or the bioconversion of phylloquinone to menaquinone-4 in the intestine of a subject.
[0274] Vitamin K2 deficiency can be diagnosed by any suitable method known in the art. For example, vitamin K deficiency can lead to reduced blood coagulation, and in severe cases, can lead to reduced coagulation, increased bleeding and increased prothrombin time. The diagnosis of vitamin K deficiency bleeding is usually indicated by prolonged activated partial thromboplastin time (APTT) and prothrombin time (PT), such as PT international normalized ratio (INR) ≥ 4 or in the presence of normal platelet count and fibrinogen content greater than 4 times the normal value (see, for example, Araki, S. and Shirahata, A., 2020. Nutrients, 12 (3), p. 780).
[0275] To enhance bone growth and / or strength or to prevent Bone loss and decreased bone strength Thus, treating and / or preventing vitamin K2 deficiency in a subject can enhance bone growth and / or bone strength or prevent bone loss and decreased bone strength in the subject (see, e.g., Hamidi, MS et al., Journal of clinical densitometry, 16(4), pp. 409-413).
[0276] In the context of the present invention, the term "enhancing bone growth and / or bone strength or limiting / preventing bone loss" may specifically refer to one or more of the following physiological processes: bone catch-up growth, bone mass acquisition, peak bone mass optimization, promoting bone formation, promoting bone anabolism, promoting bone mineralization, increasing bone mineral density and microarchitecture, regulating bone biomechanical properties and regulating the rate of bone formation and / or bone resorption, bone maintenance, and reducing bone resorption.
[0277] As used herein, "bone quality" may refer to aspects of bone composition and structure that contribute to bone strength independent of bone mineral density. These include bone turnover, microarchitecture, mineralization, microdamage, and the composition of bone matrix and minerals. Methods for measuring bone quality are known in the art.
[0278] As used herein, "promoting bone growth and / or strength" may refer to supporting normal bone growth and / or strength, for example, in childhood and adolescence. Supporting normal bone growth and / or strength may lead to normal bone anatomy and physiology. Suitable methods and parameters for determining bone growth and bone strength will be known to the technician (see, for example, Donnelly, E., 2011. Clinical Orthopaedics and Related Research, 469 (8), pp. 2128-2138). Suitably, one or more bone parameters selected from the following may be used to determine normal bone growth and / or strength: trabecular bone volume fraction (BV / TV), bone mineral density (BMD), bone mineral content (BMC), cortical bone volume (Ct.BV), inner and outer diameters, anterior and posterior diameters, bone limit force (FMax) and bone stiffness. In some embodiments, one or more bone parameters selected from the following are used to determine normal bone growth and / or strength: bone mineral density (BMD), trabecular bone volume fraction (BV / TV), cortical bone volume (Ct.BV) and bone limit force (FMax). Suitable methods for determining these parameters are available to those skilled in the art.
[0279] General nutritional provision of the composition according to the invention may also be used to prevent bone loss associated with aging and / or to protect bone cells during bone aging.
[0280] In one embodiment, the composition is for use in i) improving bone quality; ii) preventing or treating a disorder associated with an imbalance in the relationship between bone formation and bone resorption.
[0281] The so-called "reduction / inhibition of bone resorption" according to the present invention refers to the inhibition of osteoclast activity on bone tissue destruction. In order to confirm that the supply of the composition in humans or animals inhibits bone resorption, a person skilled in the art can measure the urinary excretion of deoxypyridinoline as described in the examples, and the reduction of deoxypyridinoline expression reflects the inhibition of bone resorption.
[0282] The supply of the composition according to the invention to the animal organism simultaneously induces a stimulation of bone formation and an inhibition of bone resorption, an overall increase in bone mineralization and thus an increase in bone density as a result of the induction of these two mechanisms.
[0283] In order to determine whether a subject exhibits a state of osteopenia and therefore requires the provision of a composition according to the invention, the skilled person will be able to refer in particular to the World Health Organisation (WHO) 1994 report entitled "Assessment of fracture risk and its use in screening for postmenopausal osteoporosis" (WHO Technical Series-843).
[0284] The composition according to the invention is also designed for individuals who show symptoms of bone deficiency or who may suffer from bone deficiency, i.e. due to an imbalance in the relationship between bone formation and bone resorption, which, if it persists, induces osteopenia. The composition according to the invention is also designed for individuals who show symptoms of bone deficiency caused by bone fractures, surgery or dental disease.
[0285] In particular, the composition is designed for the prevention or treatment of a disease selected from the group consisting of osteoporosis, Paget's disease, bone loss or osteolysis observed near a prosthesis, metastatic bone disease, hypercalcemia caused by cancer, multiple myeloma, periodontal disease or osteoarthritis.
[0286] As mentioned above, many disorders associated with an imbalance in bone metabolism, such as osteoporosis, develop gradually over a long period of time and require long-term treatment. Therefore, their prevention or treatment can be carried out by routine supply of the composition according to the invention, preferably in the form of a nutritional composition.
[0287] Similarly, conventional nutritional provision of the composition according to the invention to individuals, humans or animals, makes it possible to produce high bone density and increased peak bone mass by stimulating bone formation when these individuals reach adult age.
[0288] A general nutritional supply according to the composition of the present invention may also be used to prevent bone loss that occurs with aging (which may lead to osteoporosis) and / or to protect bone cells during bone aging.
[0289] Thus, in humans and other mammals, a variety of conditions are associated with abnormal metabolism of bone resorption and bone formation, leading to metabolic imbalance or bone remodeling.
[0290] Among the pathological conditions associated with an imbalance in bone metabolism, mention may be made in particular of conditions or diseases such as osteoporosis, Paget's disease, bone loss or osteolysis observed in the vicinity of a prosthesis, metastatic bone disease, hypercalcemia caused by cancer, multiple myeloma and periodontal disease. Some bone metabolic conditions or diseases may be caused by long-term immobility, such as long-term hospitalization or even after a period of weightlessness. Among the conditions associated with abnormal bone resorption, the most common is osteoporosis, the most common manifestation of which is observed in postmenopausal women. Osteoporosis is a systemic skeletal disease characterized by a decrease in bone mass and a degeneration of the microarchitecture of bone tissue, associated with an increase in bone fragility and its susceptibility to fractures. Since osteoporosis, like other conditions associated with bone loss, constitutes a chronic condition, its prevention and treatment must be planned long-term.
[0291] It is now recognized that early treatment must be preferred because there are two key phases of bone capital: the growth phase, during which maximum bone mass is acquired (peak bone mass), and aging, which influences the rate of bone loss. Therefore, prevention of osteoporosis must no longer be limited to elderly individuals.
[0292] In addition, in humans and animals, there are many conditions characterized by the need to increase bone formation. For example, in the case of bone fractures, it is necessary to stimulate bone growth to accelerate the complete repair of bone. This need also exists in periodontal disease, bone metastatic diseases, osteolytic diseases and conditions that require the repair of connective tissue, such as the healing or regeneration of cartilage defects or wounds. In the case of primary and secondary hyperparathyroidism, as well as in osteoporosis associated with diabetes and osteoporosis associated with glucocorticoids, it is also necessary to stimulate bone growth.
[0293] Methods for promoting catch-up growth
[0294] Treating and / or preventing vitamin K2 deficiency in a subject may therefore promote catch-up growth.
[0295] As used herein, "catch-up growth" may refer to a heightened rate of growth that exceeds normal age limits for at least 1 year following a brief period of growth inhibition, and may be complete or incomplete (see, e.g., Wit, JM and Boersma, B., 2002. Journal of Pediatric Endocrinology and Metabolism, 15, pp. 1229-1242).
[0296] Suitable methods and parameters for determining catch-up growth are known to those skilled in the art. Suitably, a height velocity or height standard deviation score can be used to determine catch-up growth (see, e.g., Frongillo, EA, Leroy, JL and Lapping, K., 2019. Advances in Nutrition, 10 (3), pp. 372-379 and Desmond, C. and Casale, D., 2017. PloS one, 12 (12), pp. e0189135).
[0297] In some embodiments, catch-up growth is measured in absolute terms of linear growth (i.e., a reduction in height deficit from a healthy reference population mean). In some embodiments, catch-up growth is measured in relative linear growth (i.e., an improvement in height-for-age z score and / or passing a -2SD or -1SD cutoff).
[0298] Example
[0299] The present invention is further described with reference to the following examples. It should be understood that the invention as claimed is not intended to be limited in any way by these examples.
[0300] Example 1 - Promoting Vitamin K2 Production in the Gastrointestinal Tract
[0301] To assess intestinal production of vitamin K2, a human microbial ecosystem simulator was used (See Van de Wiele, T. et al., 2015. The Impact of Food Bioactives on Health: invitro and ex vivo models, pp. 305-317). The SHIME assay generally consists of colonic fermentation of a selected amount of a test compound under simulated conditions representative of the gastrointestinal tract of a subject. The production of menaquinone-7 is determined by supercritical fluid chromatography tandem mass spectrometry (SFC-MS / MS).
[0302] For this set of experiments, a two-stage batch system simulating the conditions of the upper gastrointestinal tract (upper GIT, stomach, and small intestine) and colon was used as a simplified Infant beverages based on cow's milk, also called infant formula milk, containing minerals appropriate for the age group were used in these studies.
[0303] In order to simulate the absorption process occurring in the infant small intestine, a dialysis method was applied by using a cellulose membrane with a 14 kDa cut-off. By introducing the small intestinal suspension into the dialysis membrane, molecules such as digested amino acids, sugars, micronutrients and minerals are gradually removed from the upper gastrointestinal matrix.
[0304] In addition, during the 1 hour incubation, the pH was gradually reduced from 5.5 to 3.0 during the gastric incubation to simulate the gastric pH of infants. In addition, during the first 30 minutes of the small intestinal incubation (duodenum), a fixed pH of 4.5 was implemented to allow optimal absorption of available minerals. In the subsequent 145 minutes of the small intestinal phase (jejunum + ileum), pH 7 was introduced. The milk matrix after exposure to gastric and small intestinal conditions was transferred to the colon chamber containing infant fecal samples.
[0305] Fresh stool was collected from a 12 month old infant donor. A stool suspension was prepared and mixed with a protective agent. At the beginning of the short-term colonic incubation, the test ingredients (see below) were added to a sugar-depleted nutrient medium containing basic nutrients present in the colon (e.g. glycine derived from the host, such as mucin).
[0306] In the first set of experiments, the following groups (test components) were evaluated: blank; single HMO (1.3 g / L 2FL); HMO mixture (2.5 g / L 2FL, DiFL, LNnT, LNT, and 6SL); 7 cfu / ml); single HMO + Bifidobacterium infantis; HMO mixture + Bifidobacterium infantis. The results are shown in Figure 1 The HMO mixture increased menaquinone-7 production by 65% compared to the negative control. The addition of Bifidobacterium infantis further increased menaquinone-7 production by 163% compared to the negative control.
[0307] In a second set of experiments, the following groups (test ingredients) were evaluated (in the absence of milk matrix): Blank; and HMO + BMO (7.2 g / L total). The composition of HMO and BMO is shown in the table below.
[0308]
[0309]
[0310] The results are shown in Figure 2 A. The mixture of BMO and HMO increased the production of menaquinone-7 by 29% compared to the negative control. It was further shown that a milk matrix containing a mixture of six HMOs significantly increased the production of menaquinone-7, and the addition of Bifidobacterium infantis further increased the production (see Figure 2 B).
[0311] In the final set of experiments, the following groups were evaluated (in the absence or presence of Lactobacillus rhamnosus LPR in milk matrix): blank; COS (2700 mg / L); COS (2025 mg / L) + β-glucan (675 mg / L); and COS (2025 mg / L) + β-glucan (675 mg / L) + Bifidobacterium lactis (4.5 × 10 6 cfu / ml). The results (in the absence or presence of Lactobacillus rhamnosus LPR) are shown in Figure 3 A and Figure 3 In B. In the absence of LPR, COS increased the production of MK-7 by 178%. In the presence of LPR, the addition of Bifidobacterium lactis increased the production of MK-7 by a further 22%.
[0312] Furthermore, when all groups were combined, it was shown that the addition of Lactobacillus rhamnosus LPR (4.5 × 10 7 cfu / ml) can further increase the production of vitamin K2 in the gastrointestinal tract by about 40% (see Figure 3 C).
[0313] Example 2 - Preclinical Experimental Results
[0314] Follow Figure 4 The preclinical experimental setting shown in . The number of pups per BALB / c mother was increased by 50% from D8 to D18 to induce food restriction. In both groups (normal and growth-reduced), weaning occurred at D18. Male and female mice were then fed ad libitum and supplemented with daily nutrition by pipette for 30 days.
[0315] from Figure 5 A and Figure 5 As can be seen in B, vitamin K2AD promotes bone mass by increasing trabecular bone volume (BV / TV ratio) (trend increase) and cortical bone mineral density (Ct. BMD) (significant increase).
[0316] also, Figure 6 A and Figure 6 B shows that vitamin K2AD enhances bone strength by increasing the force (Fmax) and energy (Wmax) required to reach femoral failure point
[0317] Implementation
[0318] Various preferred features and embodiments of the present invention will now be described with reference to the following numbered paragraphs (paragraphs).
[0319] 1. A prebiotic agent for use in treating and / or preventing vitamin K2 deficiency in a subject.
[0320] 2. A prebiotic agent for use according to any preceding paragraph, wherein the prebiotic agent is administered in combination with vitamin K1.
[0321] 3. The prebiotic agent used according to paragraph 2, wherein the prebiotic agent and vitamin K1
[0322] Separately, simultaneously or sequentially administered, preferably wherein the prebiotic agent and vitamin K1 are administered simultaneously.
[0323] 4. A prebiotic agent for use according to any preceding paragraph, wherein the prebiotic agent is administered in combination with a probiotic agent.
[0324] 5. The prebiotic agent for use according to paragraph 4, wherein the prebiotic agent and the probiotic agent are administered separately, simultaneously or sequentially, preferably wherein the prebiotic agent and the probiotic agent are administered simultaneously.
[0325] 6. A prebiotic agent for use according to paragraph 4 or 5, wherein the probiotic agent comprises Lactobacillus rhamnosus, Bifidobacterium infantis and / or Bifidobacterium lactis.
[0326] 7. A prebiotic agent for use according to any preceding paragraph, wherein the prebiotic agent is selected from one or more of the following: bovine milk oligosaccharides (BMO), human milk oligosaccharides (HMO), cellobiose, cellooligosaccharides (COS), inulin, lactose, fructooligosaccharides (FOS), galacto-oligosaccharides (GOS) and β-glucan.
[0327] 8. A prebiotic agent for use according to any of the preceding paragraphs, wherein the prebiotic agent is selected from one or more of the following: bovine milk oligosaccharides (BMO), human milk oligosaccharides (HMO)
[0328] mixture and cellooligosaccharides (COS).
[0329] 9. A prebiotic agent for use according to any preceding paragraph, wherein the prebiotic agent comprises an amount of about 80 wt % to about 100 wt % relative to the total weight of the prebiotic agent.
[0330] BMO.
[0331] 10. A prebiotic agent for use according to any preceding paragraph, wherein the prebiotic agent comprises or consists of at least one sialylated oligosaccharide, at least one fucosylated oligosaccharide and / or at least one N-acetylated oligosaccharide.
[0332] 11. The prebiotic agent for use according to paragraph 10, wherein the at least one sialylated oligosaccharide is selected from the group consisting of 3'-sialyllactose (3'-SL), 6'-sialyllactose (6'-SL), sialyllactose-N-tetrasaccharide b (LSTb), sialyllactose-N-tetrasaccharide
[0333] c (LSTc), disialyl lactose-N-tetraose and combinations thereof, preferably wherein the at least one sialylated oligosaccharide is selected from 3'-sialyllactose (3'-SL), 6'-sialyllactose (6'-SL) and combinations thereof.
[0334] 12. A prebiotic agent for use according to paragraph 10 or 11, wherein the at least one fucosylated oligosaccharide is selected from the group consisting of 2'-fucosyllactose (2'FL), 3-fucosyllactose (3FL), difucosyllactose (diFL), lactose-N-fucopentose-I (LNFP-I), lactose-N-fucopentose-II (LNFP-II), lactose-N-fucopentose-III (LNFP-III), lactose-N-fucopentose-V (LNFP-V), lactose-neofucopentose V (LNnFP-V), lactose-N-difucosylhexose-I (LNDFH-I), lactose-N-neodifucosylhexose (LNnDFH), monofucosyllactose-
[0335] N-hexose-III (MFNLH-III), difucosyllactose-N-hexose-a (DFLNHa) and combinations thereof, preferably wherein the at least one fucosylated oligosaccharide is 2'-fucosyllactose (2'FL) and / or difucosyllactose (diFL); 13. A prebiotic agent for use according to any one of paragraphs 10 to 12, wherein the at least one
[0336] The at least one N-acetylated oligosaccharide is selected from the group consisting of: N-acetyl-glucosamine, N-acetyl-galactosamine, lactose-N-tetraose (LNT), lactose-N-neotetraose (LNnT) and combinations thereof, preferably wherein the at least one N-acetylated oligosaccharide is selected from the group consisting of
[0337] Lactose-N-tetraose (LNT), lactose-N-neotetraose (LNnT) and combinations thereof. 14. A prebiotic agent for use according to any preceding paragraph, wherein the prebiotic agent comprises:
[0338] (a) from about 0.5 wt % to about 2 wt % of at least one sialylated oligosaccharide relative to the total weight of the oligosaccharide mixture;
[0339] (b) from about 2 wt % to about 6 wt % of at least one fucosylated oligosaccharide relative to the total weight of the oligosaccharide mixture; and / or
[0340] (c) from about 1 wt % to about 4 wt % of at least one N-acetylated oligosaccharide, relative to the total weight of the oligosaccharide mixture.
[0341] 15. A prebiotic agent for use according to any preceding paragraph, wherein the prebiotic agent comprises or consists of cellooligosaccharides (COS).
[0342] 16. A prebiotic agent for use according to any preceding paragraph, wherein the prebiotic agent is administered to the subject in a total amount of about 0.5 g / day to about 10 g / day.
[0343] 17. A prebiotic agent for use according to any preceding paragraph, wherein vitamin K1 is present in an amount of about 5 μg /
[0344] An amount of about 100 μg / day to about 100 μg / day is administered to the subject.
[0345] 18. A prebiotic agent for use according to any preceding paragraph, wherein the probiotic agent is present in an amount of about
[0346] 10 6 cfu / day to about 10 12 A total amount of 10 cfu / day was administered to the subject.
[0347] 19. A prebiotic agent for use according to any preceding paragraph, wherein the prebiotic agent is provided in the form of a nutritional composition.
[0348] 20. A prebiotic agent for use according to any preceding paragraph, wherein the prebiotic agent is provided in the form of a medical food product for clinical nutrition.
[0349] 21. A prebiotic agent for use according to paragraph 19 or 20, wherein the composition comprises the prebiotic agent in a total amount of about 0.5 g / 100 g to about 10 g / 100 g on a dry weight basis.
[0350] 22. A prebiotic agent for use according to any one of paragraphs 19 to 21, wherein the composition comprises vitamin K1 in an amount of about 5 μg / 100 g to about 100 μg / 100 g on a dry weight basis.
[0351] 23. A prebiotic agent for use according to any one of paragraphs 19 to 22, wherein the composition comprises about 10 6 cfu / 100g to about 10 12 cfu / 100g of probiotics.
[0352] 24. A prebiotic agent for use according to any preceding paragraph, wherein the subject is an infant, toddler or child.
[0353] 25. A prebiotic agent for use according to any preceding paragraph, wherein the subject suffers from or is at risk of suffering from vitamin K2 deficiency.
[0354] 26. A prebiotic agent for use according to any preceding paragraph, wherein the subject has or is at risk of developing dyslipidemia, diabetes, thalassemia major (TM), cystic fibrosis (CF), inflammatory bowel disease (IBD) or chronic liver disease.
[0355] 27. A prebiotic agent for use according to any preceding paragraph, wherein the subject suffers from bone
[0356] or being at risk of having decreased growth and / or bone strength.
[0357] 28. A prebiotic agent for use according to any preceding paragraph, wherein the prebiotic agent treats and / or prevents vitamin K2 deficiency by promoting vitamin K2 production in the intestinal tract of the subject.
[0358] K2 deficiency.
[0359] 29. A prebiotic agent for use according to any preceding paragraph, wherein the prebiotic agent treats and / or prevents vitamin K2 deficiency by promoting de novo production of menaquinone-7 and / or bioconversion of phylloquinone to menaquinone-4 in the gut of the subject.
[0360] 30. Use of a prebiotic agent in the manufacture of a medicament for treating and / or preventing vitamin K2 deficiency in a subject.
[0361] 31. A method for treating and / or preventing vitamin K2 deficiency in a subject in need thereof, the method comprising administering to the subject an effective amount of a prebiotic agent.
[0362] 32. Use of a prebiotic agent to promote the production of vitamin K2 in the intestine of a subject.
[0363] 33. The use according to paragraph 32, wherein the prebiotic agent promotes the de novo production of menaquinone-7 and / or the bioconversion of phylloquinone to menaquinone-4 in the intestinal tract of the subject.
[0364] Although the present invention has been described by way of example, it should be appreciated that variations and modifications may be made without departing from the scope of the invention as defined in the claims. In addition, if known equivalents exist for specific features, such equivalents should be incorporated as if explicitly mentioned in this specification.
Claims
1. A prebiotic agent for use in treating and / or preventing vitamin K2 deficiency in a subject.
2. The prebiotic agent for use according to claim 1, further comprising a vitamin mixture to promote vitamin K2 production in the intestine of the subject.
3. A prebiotic agent for use according to claim 1 or 2, wherein the vitamin mixture comprises vitamin K2, A and / or D.
4. A prebiotic agent for use according to any preceding claim, wherein the prebiotic agent is administered in combination with vitamin K1.
5. A prebiotic agent for use according to any preceding claim, wherein the prebiotic agent is administered in combination with a probiotic agent.
6. The prebiotic agent for use according to claim 5, wherein the probiotic agent comprises Lactobacillus rhamnosus, Bifidobacterium infantis and / or Bifidobacterium lactis.
7. A prebiotic agent for use according to any preceding claim, wherein the prebiotic agent is selected from one or more of the following: bovine milk oligosaccharides (BMO), human milk oligosaccharides (HMO), cellobiose, cellooligosaccharides (COS), inulin, lactose, fructooligosaccharides (FOS), galacto-oligosaccharides (GOS) and β-glucan, preferably wherein the prebiotic agent is selected from one or more of the following: bovine milk oligosaccharides (BMO), a mixture of human milk oligosaccharides (HMO) and cellooligosaccharides (COS).
8. A prebiotic agent for use according to any preceding claim, wherein the prebiotic agent comprises BMO in an amount of about 80 wt% to about 100 wt% relative to the total weight of the prebiotic agent.
9. A prebiotic agent for use according to any preceding claim, wherein the prebiotic agent comprises or consists of HMOs, preferably wherein the prebiotic agent comprises or consists of at least one sialylated oligosaccharide, at least one fucosylated oligosaccharide and / or at least one N-acetylated oligosaccharide, more preferably wherein: (a) the at least one sialylated oligosaccharide is selected from the group consisting of: 3'-sialyllactose (3'-SL), 6'-sialyllactose (6'-SL), sialyllactose-N-tetraose b (LSTb), sialyllactose-N-tetraose c (LSTc), disialyllactose-N-tetraose and combinations thereof, preferably wherein the at least one sialylated oligosaccharide is selected from the group consisting of 3'-sialyllactose (3'-SL), 6'-sialyllactose (6'-SL) and combinations thereof; (b) the at least one fucosylated oligosaccharide is selected from the group consisting of 2'-fucosyllactose (2'FL), 3-fucosyllactose (3FL), difucosyllactose (diFL), lactose-N-fucopentose-I (LNFP-I), lactose-N-fucopentose-II (LNFP-II), lactose-N-fucopentose-III (LNFP-III), lactose-N-fucopentose-V (LNFP-V), lactose-neofucopentose-V (LNFP-V), lactose-N-fucopentose-V (LNFP-V), lactose-N-fucopentose-I (LNFP-I), lactose-N-fucopentose-II (LNFP-II), lactose-N-fucopentose-III (LNFP-III), lactose-N- ...II (LNFP-II), lactose-N-fucopentose-III (LNFP-III), lactose-N-fucopentose-III (LNFP-III), lactose-N-fucopentose-III (LNFP-III), lactose-N-fucopentose-III (LNFP-III), lactose-N-fucopentose-III (LNFP-III), lactose-N-fucopentose-III (LNFP-III), lactose-N-fucopentose-III (LNFP-III), lactose-N-fucopentose-III (LNFP-III), lactose-N-fucopentose-III (LNFP- NnFP-V), lactose-N-difucosylhexose-I (LNDFH-1), lactose-N-neodifucosylhexose (LNnDFH), monofucosyllactose-N-hexose-III (MFNLH-III), difucosyllactose-N-hexose-a (DFLNHa) and combinations thereof, preferably wherein the at least one fucosylated oligosaccharide is 2'-fucosyllactose (2'FL) and / or difucosyllactose (diFL); and / or (c) the at least one N-acetylated oligosaccharide is selected from the group consisting of N-acetyl-glucosamine, N-acetyl-galactosamine, lactose-N-tetraose (LNT), lactose-N-neotetraose (LNnT) and combinations thereof, preferably wherein the at least one N-acetylated oligosaccharide is selected from the group consisting of lactose-N-tetraose (LNT), lactose-N-neotetraose (LNnT) and combinations thereof.
10. A prebiotic agent for use according to any preceding claim, wherein the prebiotic agent comprises or consists of COS.
11. A prebiotic agent for use according to any preceding claim, wherein the prebiotic agent is administered to the subject in a total amount of about 0.5 g / day to about 10 g / day.
12. A prebiotic agent for use according to any preceding claim, wherein vitamin K1 is administered to the subject in an amount of about 5 μg / day to about 100 μg / day, and / or wherein the probiotic agent is administered to the subject in an amount of about 10 6 cfu / day to about 10 12 A total amount of 10 cfu / day was administered to the subject.
13. A prebiotic agent for use according to any preceding claim, wherein the prebiotic agent is provided in the form of a nutritional composition.
14. A prebiotic agent for use according to any preceding claim, wherein the subject is an infant, toddler or child.
15. A prebiotic agent for use according to any preceding claim, wherein the subject suffers from or is at risk of suffering from dyslipidemia, diabetes, thalassemia major (TM), cystic fibrosis (CF), inflammatory bowel disease (IBD) or chronic liver disease and / or wherein the subject suffers from or is at risk of suffering from reduced bone growth and / or bone strength.
16. A prebiotic agent for use according to any preceding claim, wherein the prebiotic agent enhances bone growth, bone mineralization and / or bone strength or limits / prevents bone loss and bone strength in the subject.
17. A prebiotic agent for use according to any preceding claim, wherein the prebiotic agent treats and / or prevents vitamin K2 deficiency by promoting vitamin K2 production in the intestinal tract of the subject.
18. Use of a prebiotic agent to promote the production of vitamin K2 in the intestine of a subject.
